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A1— Desmosomal molecules in and out of junctions
Kathleen J. Green, Adi Dubash, Lisa M. Godsel
Departments of Pathology and Dermatology, Northwestern
University Feinberg School of Medicine, Chicago, IL, USA
kgreen@northwestern.edu
Desmosomes are intercellular junctions that anchor the
intermediate filament (IF) cytoskeleton to sites of strong
intercellular adhesion, and play a critical role in ensuring
mechanical integrity of the skin and the heart. Desmo-
some building blocks come primarily from three protein
families. Transmembrane members of the cadherin fami-
ly, the desmogleins and desmocollins, cooperate to form
the adhesive interface. Within the junctional plaque, the
cytoplasmic tails of the cadherins provide a scaffold for
armadillo family members including plakoglobin and
plakophilins (PKPs) 1-3 and the IF-binding protein, des-
moplakin (DP), which in turn anchors the strain-bearing
IF cytoskeleton to the plaque. In cardiac muscle, desmo-
some molecules are major architectural components of
the intercalated discs, highly organized regions of the
plasma membrane comprising components of adherens
junctions, gap junctions, and desmosomes that together
coordinate mechanical and electrochemical signaling be-
tween adjacent cardiac myocytes. In vertebrates, postna-
tal remodeling of these specialized regions of the plasma
membrane occurs, giving rise to the area composita in
which desmosomal building blocks are intermixed with
components of adherens junctions.
The crucial functions of desmosome molecules in epithelial
and cardiac tissues are highlighted by the discovery of
mutations that cause skin and heart disease. While interfer-
ence with the architectural roles of desmosome molecules
has been assumed to make an important contribution to
tissue responses that lead to disease pathogenesis, functions
that transcend their well-established roles in adhesion and
IF-anchorage are emerging. Desmosome molecules have
recently been shown to guide the remodeling of microtu-
bules during epidermal morphogenesis, and also govern
actin remodeling by regulating Rho GTPases during junc-
tion assembly.
Of particular interest is the desmosomal armadillo protein
plakophilin 2 (PKP2), which is reported as the most frequent
target for mutation in arrhythmogenic right ventricular car-
diomyopathy (ARVC), a leading cause of sudden cardiac
death in the young. We previously showed that in epithelial
cells, PKP2 regulates the localization and activity of RhoA
to locally control actomyosin contractile signaling important
for cell junction formation, while keeping global RhoA
signaling in check. In the heart, signaling through RhoA
and its downstream effectors is critical for normal cardiac
development and physiology. Indeed, our data show that
PKP2 silencing results in elevated RhoA and disruption of
actin organization in cardiac myocytes. Further, loss of
PKP2 or its fellow armadillo protein plakoglobin leads to
elevated expression of target genes of the transcriptional
regulator SRF (serum response factor), which is activated
in a RhoA-dependent fashion, and along with Rho plays
essential roles in cardiac development, hypertrophy and
fibrosis. These data suggest a new cellular pathway through
which desmosome deficiency could contribute to pathogen-
esis in ARVC.
A2— Alpha-catenins: emerging targets for diseases
Jolanda van Hengel
1,J i f e nL i
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1,E r h e
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2, Koen Tyberghein
1, Xiying Shang
2, Riet
De Rycke
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1, and Glenn L. Radice
2
(1) Department for Molecular Biomedical Research, Flan-
ders Interuniversity Institute for Biotechnology (VIB) and
Ghent University, B-9052, Ghent, Belgium
(2) Center for Translational Medicine, Department of Med-
icine, Thomas Jefferson University, Philadelphia, PA, USA
Jolanda.vanhengel@dmbr.vib-ugent.be
The adherens junction (AJ) is a type of cell–cell junction
that develops near the apical surface of polarized epithelial
cells. Together with a bundle of cortical actin filaments, the
AJ is organized as a molecular belt. The AJ comprises
cadherins, catenins, and other associated proteins. Cadherins
interact homophilically via their extracellular domain, and
physically link the adjacent cell membranes. The cytoplas-
mic region of classic cadherins binds β-catenin, which in
turn associates with α-catenin. Alpha-catenin is indispens-
able for cadherin-mediated cell adhesion. In the absence of
α-catenin, the AJ is disrupted, and the apical actin belt
dissociates from the cadherin–catenin complex. It was com-
monly believed that the cadherin–catenin complex is phys-
ically linked to actin fibers via α-catenin, and that this
linkage is crucial for maintenance of the AJ. However, this
model has been challenged by the recently revealed inability
of the reconstructed cadherin–catenin complex to directly
bind actin filaments in vitro (Drees et al. 2005; Yamada et al.
2005). However, a number of mechanisms can be proposed
to reconcile these observations. One possibility is that addi-
tional mediators serve as a bridge between the cadherin-
bound α-catenin and F-actin. Three homologous α-catenin
proteins are known: the ubiquitously expressed αE-catenin,
the neurally expressed αN-catenin, and αT-catenin with a
restricted expression pattern. AlphaT-catenin is especially
abundant in heart tissue, where it is co-expressed with
αE-catenin in areae compositae, which are present at
338 Cell Tissue Res (2012) 348:335–370the intercalated discs (ICD). In vitro, αN- and αT-
catenin can substitute for the adhesive functions of
αE-catenin, but their restricted expression patterns in
vivo indicate that they have tissue-specific functions.
This hypothesis was confirmed by the inability of en-
dogenous αT-catenin expression to rescue a heart-
specific αE-catenin knock-out in mice (Sheikh et al.
2006). We have shown that αT-catenin has the follow-
ing isoform-specific function: it interacts specifically
with plakophilins (PKP), whereas αE- and αN-catenin
cannot (Goossens et al. 2007). To investigate the func-
tion of alphaT-catenin, we generated a loss-of-function
model in mouse. AlphaT-catenin-null mice are viable,
but they exhibit progressive cardiomyopathy (Li et al.
2011). We observed reduced expression of PKP-2 in the
ICD of αT-catenin-null myocardium. Furthermore, Cx43
was reduced at the ICD, including its co-localization
with N-cadherin. This finding suggests that αT-catenin
may function synergistically with desmosomal PKP-2 to
stabilize gap junctions at the area composita.T h i sg a p
junction remodeling was associated with an increased
incidence of ventricular arrhythmias in αT-catenin-null
mice when subjected to acute ischemia.
DreesF,PokuttaS,YamadaS,NelsonWJ,WeisWI(2005)α-Cateninisa
molecular switch that binds E-cadherin-β-catenin and regulates
actin-filament assembly. Cell 123:903–915
Goossens S, Janssens B, Bonné S, De Rycke R, Braet F., van Hengel J,
van Roy F (2007) A unique and specific interaction between αT-
catenin and plakophilin-2 in the area composita, the mixed-type
junctional structure of cardiac intercalated discs. J Cell Sci
120:2126–2136
Li J, Goossens S, van Hengel J, Gao E, Cheng L, Tyberghein K, Shang
X, De Rycke R, van Roy F, Radice GL (2012) Loss of alphaT-
catenin alters the hybrid adhering junctions in the heart and leads
to dilated cardiomyopathy and ventricular arrhythmia following
acute ischemia. J Cell Sci 125:1058–1067
Sheikh F, Chen Y, Liang X, Hirschy A, Stenbit AE, Gu Y, Dalton ND,
Yajima T, Lu Y, Knowlton KU, Peterson KL, Perriard J-C, Chen J
(2006) α-E-catenin inactivation disrupts the cardiomycyte adhe-
rens junction, resulting in cardiomyopathy and susceptibility to
wall rupture. Circulation 114:1046–1055
Yamada S, Pokutta S, Drees, F, Weis WI, Nelson WJ (2005) Decon-
structing the cadherin-catenin-actin complex. Cell 123:889–901
A3— Catenins: multi-function proteins involved in cell
adhesion, communication, and signaling in the heart
Jifen Li
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1, Lan Cheng
1, Erhe Gao
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Roy
3, Glenn L. Radice
1
(1) Center for Translational Medicine, Department of Med-
icine, Thomas Jefferson University, Philadelphia, PA, USA
(2) Molecular Dermatology, Institute of Animal Pathology,
University of Bern, Bern, Switzerland
(3) Department of Molecular Biomedical Research,
Flanders Interuniversity Institute for Biotechnology
(VIB)-Ghent University, B-9052, Ghent, Belgium
Glenn.Radice@jefferson.edu
Efficient cardiac contractile function is highly dependent
upon the coordinated mechanical and electrical activation
of the myocardial tissue. Many of the molecular components
required for mechano-electrical coupling in the heart are
localized at the end-to-end connection between myocytes
called the intercalated disc (ID). The ID consists of three
main junctional complexes: adherens junctions and desmo-
somes provide strong cell–cell adhesion, and gap junctions
provide electrical coupling between the myocytes. ID struc-
ture is dependent on N-cadherin, the only classical cadherin
expressed in the myocardium (Kostetskii et al. 2005).
Cadherin-mediated adhesion requires interaction with the
actin cytoskeleton via a family of proteins called catenins.
Whether the different catenin subtypes have distinct or
synergistic functions in the heart is not clear.
Mutations in γ-catenin (also known as plakoglobin) are
associated with arrhythmic right ventricular cardiomyopathy
(ARVC), a hereditary heart-muscle disease that causes sud-
den cardiac death (SCD) in young people. To investigate the
role of PG in ARVC, we generated a cardiac-specific knock-
out (CKO) of the plakoglobin (JUP) gene in mice (Li et al.
2011). Interestingly, despite gap junction remodeling, PG
CKO mice have no apparent conduction abnormality and
survive longer than expected. Importantly, the PG homolog,
β-catenin, showed increased association with the gap junc-
tion protein, connexin43 (Cx43) in PG CKO hearts. To
determine whether β-catenin protects PG CKO animals
from sudden arrhythmic death, we generated mice lacking
both PG and β-catenin specifically in the heart (i.e., double
knockout, DKO). The PG/β-catenin DKO mice exhibited
acute cardiomyopathy, fibrous tissue replacement, and con-
duction abnormalities resulting in SCD 3–5 months after
deleting both genes. In contrast to the PG and β-catenin
single mutants, N-cadherin was significantly reduced at the
ID in the PG/β-catenin DKO mice. Moreover, the ID struc-
ture was disrupted in the PG/β-catenin DKO hearts, consis-
tent with the loss of adherens junction and desmosome
proteins from the ID. Collectively, our results demonstrate
that PG is more important for the structural integrity of the
heart than β-catenin; however, β-catenin maintains gap
junctions in the absence of PG, indicating that these
proteins cooperate to maintain electrical coupling in
the heart.
There are two α-catenin subtypes expressed in the myocar-
dium, αE-catenin and αT-catenin; together, they are thought
to modulate interactions between N-cadherin/catenin com-
plex and the actin cytoskeleton. A novel αT-catenin KO
mouse model demonstrates for the first time how
Cell Tissue Res (2012) 348:335–370 339perturbation in αT-catenin can affect both PKP-2 and Cx43,
thus highlighting the importance of understanding the cross-
talk between the junctional proteins of the area composita
and its implications for arrhythmogenesis (Li et al. 2012).
Kostetskii I, Li J, Xiong Y, Zhou R, Ferrari VA, Patel VV, Molkentin
JD, Radice GL (2005) Induced deletion of the N-cadherin gene in
the heart leads to dissolution of the intercalated disc structure.
Circ Res 96:346–354
Li J, Swope D, Raess N, Cheng L, Muller EJ, Radice GL (2011)
Cardiac tissue-restricted deletion of plakoglobin results in pro-
gressive cardiomyopathy and activation of β-catenin signaling.
Mol Cell Biol 31:1134–1144
Li J, Goossens S, van Hengel J, Gao E, Cheng L, Tyberghein K, Shang
X, De Rycke R, van Roy F, Radice GL (2012) Loss of alphaT-
catenin alters the hybrid adhering junctions in the heart and leads
to dilated cardiomyopathy and ventricular arrhythmia following
acute ischemia. J Cell Sci 125:1058–1067
A4— Transgenic overexpression of the intercalated disc
protein myozap causes protein aggregate-associated
cardiomyopathy
Derk Frank
1, Thalia S. Seeger
2, Claudia Rohr
2, Christian
Kuhn
1, Christine Grund
3, Rainer Will
2, Werner W. Franke
3,
Hugo A. Katus
2, Norbert Frey
1
(1) Dept. of Cardiology and Angiology, UK-SH, Kiel,
Germany
(2) Dept. of Internal Medicine III, University of Heidelberg,
Germany
(3) Helmholtz Group Cell Biology, DKFZ, Heidelberg,
Germany
Norbert.Frey@uk-sh.de
The intercalated disc (ID) is an important component of
the cell–cell contact structures of cardiomyocytes. During
the last decade, it became evident that the molecular
components of the ID are critical regulators in the path-
ogenesis of inherited cardiac disease (van Tintelen et al.
2007). We were able recently to identify and characterize
a novel cardiac-enriched ID protein, termed myozap. It
interacts with several other ID proteins including
desmoplakin.
Mechanistically, it represents a positive modulator of the
Rho-dependent SRF pathway linking the ID to gene regu-
lation processes and actin dynamics (Seeger et al. 2010). To
further insight in myozap’s function in vivo, we generated a
mouse model with cardiac-restricted overexpression of
myozap cDNA using the αMHC promoter. These mice
developed substantial cardiac hypertrophy (heart weight/
tibia length +43 %, p < 0.01, n 0 8–10) as well as progres-
sive LV dilation (LVEDD +20 %, p < 0.01). Consistently,
myozap-transgenic hearts displayed upregulation of the
hypertrophy-associated “fetal” gene program (e.g., ANF
4.3-fold, p <0 . 0 0 1 , a n d B N P 2 . 2 - f o l d , p <0 . 0 1 , n 0 7–9).
Next, myozap transgenic animals were subjected to var-
ious forms of stress, including voluntary running wheel
exercise, which led to an accelerated cardiomyopathy
with premature LV dysfunction and dilation. Moreover,
chronic infusion of the alpha-agonist phenylephrine (PE)
caused significant lethality in myozap-Tg [n 0 5/8,
p < 0.05 vs WT (1/7)]. Unexpectedly, on the ultra-
structural level, we were able to detect bulky protein
aggregates containing myozap, desmoplakin, and other
ID proteins. This aggregate-associated pathology closely
resembled the changes in the hearts of patients suffering
from desminopathies (Goldfarb and Dalakas 2009). It
should be noted that desmin was not detectable in the
aggregates of myozap tansgenic mice, but was displaced
from the ID.
Taken together, cardiac overexpression of the novel ID
protein myozap leads to hypertrophy and dilated cardiomy-
opathy, accompanied by protein aggregates and associated
with sudden death upon PE treatment. Further analyses of
this transgenic model may help to understand the pathogen-
esis and pathophysiology of protein aggregate-associated
cardiomyopathies.
Goldfarb LG, Dalakas MC. (2009) Tragedy in a heartbeat: malfunc-
tioning desmin causes skeletal and cardiac muscle disease. J Clin
Invest 119:1806–1813
Seeger TS, Frank D, Rohr C, Will R, Just S, Grund C, Lyon R, Luedde
M, Koegl M, Sheikh F, Rottbauer W, Franke WW, Katus HA,
Olson EN, Frey N (2010) Myozap, a novel intercalated disc
protein, activates serum response factor-dependent signaling and
is required to maintain cardiac function in vivo. Circ Res
106:880–890
van Tintelen JP, Hofstra RM, Wiesfeld AC, van den Berg MP, Hauer
RN, Jongbloed JD. (2007) Molecular genetics of arrhythmogenic
right ventricular cardiomyopathy: emerging horizon? Curr Opin
Cardiol 22:185–192
A5— The intercalated disc — a truly special type
of cell-cell contact in dilated cardiomyopathy
Alain Hirschy, Elisabeth Ehler
King’s College London BHF Research Excellence Centre,
The Randall Division of Cell and Molecular Biophysics and
The Cardiovascular Division, New Hunt’s House, Guy’s
Campus, London SE1 1UL, United Kingdom
elisabeth.ehler@kcl.ac.uk
Two multiprotein complexes are essential for proper func-
tioning of the heart: the myofibrils are responsible for car-
rying out the contractile work, and the intercalated disc, a
specialised type of cell–cell contact, is indispensable for
proper mechanical and electrochemical contact between
the individual cardiomyocytes. Both structures are
340 Cell Tissue Res (2012) 348:335–370characterized by their extremely regular arrangement, which
in case of the intercalated disc is only achieved after birth.
We have shown previously that alterations in intercalated
disc composition are a hallmark of dilated cardiomyopathy
(DCM) in mice and men (Ehler et al., 2001). There is an
upregulation of expression of proteins that are involved in
the anchoring of actin filaments accompanied by an in-
creased convolution of the plasma membrane. This probably
leads to an overall stiffening of the cell–cell contacts. In the
rodent DCM heart, there is also a reduction in the expression
of gap junction proteins, which is expected to lead to de-
creased intercellular communication. Since stoichiometry is
clearly important for proper function, we have decided to
challenge it by gain and loss of function experiments, target-
ing the adherens junction protein beta-catenin.
In our system, the postnatal loss of beta-catenin in cardio-
myocytes has comparatively little effect on heart function;
however, when we overexpress beta-catenin in the heart we
observe a dramatic phenotype of DCM, with all the mice
dead by 5 months of age (Hirschy et al., 2010). Interestingly,
despite an excess of beta-catenin per targeted cell, we never
observed any beta-catenin in the nucleus of postnatal car-
diomyocytes. We conclude that increased amounts of beta-
catenin at the intercalated disc are not tolerated by the heart,
but that nuclear beta-catenin signaling is probably not very
relevant in the fully differentiated cardiomyocyte.
Ehler E, Horowits R, Zuppinger C, Price RL, Perriard E, Leu M,
Caroni P, Sussman M, Perriard J-C (2001) Alterations at the
intercalated disk associated with the absence of muscle LIM
protein. J. Cell Biol 153:763–772
Hirschy A, Croquelois A, Perriard E, Schoenauer R, Agarkova I,
Hoerstrup SP, Taketo MM, Pedrazzini T, Perriard J-C, Ehler D
(2010) Stabilised beta-catenin in postnatal ventricular myocardium
leads to dilated cardiomyopathy and premature death. Basic Res
Cardiol 105:597–608
A6— The connexin carboxyl terminus and cardiac gap
junction organization
Robert G. Gourdie
Department of Regenerative Medicine and Cell Biology and
Clemson-MUSC Bioengineering Program, Medical Univer-
sity of South Carolina, Charleston, SC, USA
gourdier@musc.edu
The precise spatial order of gap junctions at intercalated
disks in adult ventricular myocardium is thought vital for
maintaining cardiac synchrony. Breakdown or remodeling
of this order is a hallmark of arrhythmic disease of the heart.
The principal component of gap junction (GJ) channels
between ventricular cardiomyocytes is connexin43 (Cx43).
Protein–protein interactions and modifications of the
carboxyl-terminus (CT) of Cx43 are key determinants of
GJ function, size, distribution, and organization during nor-
mal development and in disease processes. This talk will
focus on the work of my lab on protein interactions at the
Cx43 CT in the regulation of GJ organization. There will be
a particular emphasis on the role of the protein Zonula
Occludens-1 (ZO-1). Topics covered will include our recent
identification of the perinexus — a novel, hemichannel-
containing domain surrounding the GJ that is enriched for
Cx43-ZO-1 interaction.
Our recent studies of the mode-of-action of a peptide based
on the Cx43 CT that inhibits GJ remodeling at injury border
zone (IBZ) and reduces inducible arrhythmias following
cryo-infarction of the left ventricle will be presented. Also
discussed will be preliminary data on potential assignments
of the Cx43 CT in myocyte–fibroblast interaction at the IBZ
and ZO-1 interaction with Cx40 and Cx45 — connexins
expressed in the conduction system.
A7— Outside-in and inside-out signaling through
cell–cell and cell–matrix adhesion complexes promotes
myofibril organization in striated muscle
Mark W. Russell
Division of Pediatric Cardiology, Department of Pediatrics
and Communicable Dieases, University of Michigan, Ann
Arbor, MI, USA
mruss@med.umich.edu
During development, cardiac and skeletal myoblasts differ-
entiate into myocytes and skeletal myotubes with mature
contractile structures that are precisely oriented with respect
to surrounding cells and tissues. Establishment of this highly
ordered structure requires coordinate and reciprocal interac-
tions between the differentiating myocytes and the extracel-
lular environment, including neighboring cells and the
surrounding extracellular matrix. “Outside-in” signals from
the extracellular environment result in changes to myocyte
morphology, and promote new myofibril assembly; in re-
turn, “inside-out” signals pattern adjoining cells and the
extracellular matrix, and coordinate the assembly and orga-
nization of myofibrils across cells and tissues. Communica-
tion between the cell and extracellular environment is
mediated by transmembrane adhesion complexes, the com-
position and complexity of which depend on the cell type
and degree of differentiation. In cardiac myocytes, axial
connections occur at intercalated disks in which desmo-
somes (maculae adhaerentes), fasciae adhaerentes, and gap
junctions form mechanical and electrochemical communi-
cations between adjacent cells. Examination of remodeling
adult rat cardiac myocytes in primary culture suggests that
outside-in signals from surrounding cells establish a well-
Cell Tissue Res (2012) 348:335–370 341defined axis of contraction, resulting in cytoskeletal
remodeling and reorganization of the myofibrils. Inside-
out signals restrict the adhesive contacts to the termini
of the reorganized myofibrils, supporting the layered
addition of armadillo family proteins and cytoskeletal
adaptors to the cadherin- and desmosomal cadherin–
based adhesive contact. A similar process occurs at
integrin-based adhesion contacts within the costameres
of cardiac and skeletal muscle. At those sites, outside-in
and inside-out signals transmitted through the adhesion
complexes promoted organization of the internal struc-
ture of the myocyte and translation of those structural
cues to surrounding cells and tissues. Our findings sup-
port a model of myofibril assembly and organization as
a dynamic process involving the interaction of intracel-
lular compartments with specialized transmembrane ad-
hesion domains. Identification of the linking elements
that promote the coordinated remodeling of the sarco-
mere and cell–cell and cell–matrix contacts will be es-
sential in developing strategies to prevent muscle injury
and promote muscle repair in patients with cardiac and
skeletal myopathies and muscular dystrophies.
A8— Desmin as a major player in heart failure and a
potential link between ARVD/C and DCM
Yassemi Capetanaki
Division of Cell Biology, Center of Basic Research I, Bio-
medical Research Foundation, Academy of Athens, Athens,
Greece
ycapetanaki@bioacademy.gr
It has been demonstrated that gene inactivation in mice or
mutations in humans in the major intermediate filament
protein desmin leads to all forms of cardiomyopathy
(DCM, HCM, RCM, ARVD/C) and eventually heart failure.
Desmin forms a continuous network connecting the contrac-
tile apparatus to the sarcolemma (costameres & intercalated
discs), nucleus, and several membranous organelles. Muta-
tions in proteins that associate to the desmin network direct-
ly or indirectly also lead to cardiomyopathy. Importantly, the
type of developed cardiomyopathy depends on the cardio-
myocyte structure at which the desmin network-associated
proteins are localized. Thus, costameric proteins such as
dystrophin, α-dystroglycan, and δ-sarcoglycan, nuclear pro-
teins such as the nuclear intermediate filament protein lamin
A/C, and different lamin-associated proteins, such as
LAP2alpha and emerin, and finally, at the Z-disc region,
proteins such as plectin and the chaperon protein αB-
crystallin, are associated to DCM. On the other hand, muta-
tions in genes encoding several proteins of the area compo-
sita (Franke et al. 2007) of the intercalated disc, such as
desmoplakin, plakoglobin, plakophilin 2, desmoglein 2, and
desmocollin, have been identified as the genetic basis of
ARVD/C. Interestingly, preliminary genotype–phenotype
assessment indicates that mutations affecting the outer dense
plaque of the desmosome result in ARVD/C, while muta-
tions at the inner dense plaque, particularly affecting the
desmin-binding site of desmoplakin, result in ARVD/C with
left ventricular involvement and extensive overlap with
DCM. Similarly, the S13F desmin mutation, identified re-
cently in patients with ARVD/C (Van Spaendonck-Zwarts et
al. 2011), is the most upstream mutation of the desmin head
domain found so far, and the observation that this mutation
results in abnormalities at the intercalated disc region, po-
tentially by disruption of desmin-desmoplakin association,
is important and could allow the molecular understanding of
the transition from mainly ARVD/C to ARVDC/DCM and
to mainly DCM development.
The most common desmin-related heart disease is the TNF-
α linked heart failure. We have demonstrated that activation
of caspases by cytokines, such as TNF-α, known to cause
heart failure, leads to desmin cleavage and aggregate for-
mation, loss of desmin and other proteins (at least β-catenin
and desmoplakin) from intercalated discs (IDs), destabiliza-
tion of IDs, mitochondrial defects, and heart failure. Strik-
ingly, we have found that when the WT desmin is replaced
by a caspase-resistant desmin (D263E), in TNF-α over-
expressing mouse heart, these pathological features are
greatly ameliorated, demonstrating that desmin is a major
target and plays a crucial role in the development of the
TNF-α-induced heart pathology (Panagopoulou et al.
2008). As our studies have demonstrated (reviewed by
Capetanaki et al. 2007), the desmin null heart failure
model possesses a combination of the pathophysiology
of most types of cardiomyopathy, particularly DCM and
ARVD/C (characterized by cell death, extensive inflam-
mation, fibrosis, and degeneration, in both right and left
ventricle, followed by systolic dysfunction and conduc-
tion system defects). Therefore, we use this model for
several studies aimed to both unravel the mechanism of
cardiomyopathy and heart failure development, as well as
to develop therapeutic strategies for the disease. The
successes towards these goals, and specifically the rescue
of the desmin deficient heart failure by αB-cystallin
overexpression, will be discussed.
Capetanaki Y, Bloch RJ, Kouloumenta A, Mavroidis M,Psarras S
(2007) Muscle intermediate filaments and their links to mem-
branes and membranous organelles. Exp Cell Res 313:2063–
2076
Franke WW, Schumacher H, Borrmann CM, Grund C, Winter-
Simanowski S, Schlechter T, Pieperhoff S, Hofmann I (2007)
The area composita of adhering junctions connecting heart muscle
cells of vertebrates - III: assembly and disintegration of interca-
lated disks in rat cardiomyocytes growing in culture. Eur J Cell
Biol. 86:127–142
342 Cell Tissue Res (2012) 348:335–370Panagopoulou P, Davos C, Milner D, Varela E, J, Mann D, Capetanaki
Y (2008) Desmin mediates TNF-a induced aggregate formation
and intercalated disk reorganization in heart failure. J Cell Biol
181:761–775
Van Spaendonck-Zwarts KY, van Hessem L, Jongbloed JDH,
Hermien EK, de Walle HEK, Capetanaki Y, van der Kooi AJ,
van Langen IM, van den Berg MP, van Tintelen JP (2011)
Desmin related myopathy: a review and meta-analysis. Clin
Genet 80:354–366
A9— Potential and pitfalls of cellular replacement
approaches in the heart
Bernd K. Fleischmann
Institute of Physiology I, Life & Brain Center, University of
Bonn, Germany
bernd.fleischmann@uni-bonn.de
Myocardial infarction is characterized by an irreversible
loss of cardiomyocytes and scar formation, often result-
ing in heart failure. The only causal treatment currently
available is heart transplantation. However, due to
shortage of donor organs, cell replacement using pro-
genitors and/or stem cells is considered a promising
alternative approach. We have explored the plasticity
of these cells to differentiate into cardiac muscle, their
physiological integration and contribution to pump func-
tion in vivo. Heart infarctions (cryoinjury, LAD liga-
tion) were induced in mouse and progenitors/stem cells
mobilized with cytokines or directly injected into the
infarct area. We have first assessed the plasticity of
bone marrow (BM)-derived cells. These neither differ-
entiated into functional cardiac muscle or endothelial
cells, nor strongly enhanced left ventricular function.
Similar results were obtained when using BM-derived
mesenchymal stem cells. Importantly, their differentia-
tion was not restricted by the heart tissue, as calcifica-
tions and bone formation could frequently be observed.
In contrast, fetal cardiomyocytes stably engrafted into
the infarct, and enhanced left ventricular function. Fur-
thermore, the engrafted cardiac muscle cells functionally
integrated into the cardiac and strongly reduced post-infarct
arrhythmias. This was related to increased conduction veloc-
ities in areas containing the cellular grafts. We also analyzed
the potential of embryonic stem (ES) cell-derived cardiomyo-
cytes for cell replacement therapy. An antibiotic-based selec-
tion approach was used to obtain highly purified
cardiomyocytes and to avoid teratoma formation due to con-
taminating pluripotent ES cells.
Transplantation experiments revealed that co-injection of
purified cardiomyocytes and fibroblasts increased the de-
gree of engraftment, and resulted in an improvement of left
ventricular function. Thus, cardiac progenitors and ES cell-
derived cardiomyocytes stably engraft into the infarcted
myocardium and enhance heart function.
A1 0— Cellular and molecular aspects of early heart
formation
Takashi Mikawa, Michael Bressan
Cardiovascular Research Institute, University of California,
San Francisco, CA, USA
takashi.mikawa@ucsf.edu
Complex organization of the heart is established through
the orchestrated and sequential processes of commitment,
proliferation, and movements of multiple cell types. A
spatiotemporally regulated binary decision model was
once considered the major mechanism for generating
multiple cardiac cells from a common stem cell popula-
tion. This model was used to describe the genesis of
myocyte vs endocardial endothelial cell lineages and
atrial vs ventricular myocyte lineages, as well as coro-
nary endothelial vs smooth muscle lineages. Contrary to
this idea, mounting evidence collected in recent years
indicates that lineage segregation of individual cardiac
cell types actually occurs prior to arrival of their progen-
itors to the heart. The resolution of these two models lies
at the core of many controversies in cardiovascular de-
velopmental biology. They need not be mutually exclu-
sive, however. For instance, differing components of the
cardiac conduction system rely on both predetermination
of separate cell population and diversification of fate
from common precursors. We have shown that the in-
duction and patterning of the fast-conducting Purkinje
fiber network, which is mediated by hemodynamic-
activated paracrine cues, involves the recruitment of
already beating ventricular myocytes into the Purkinje
fiber lineage. Conversely, our recent data suggest that
prior to heart tube formation the pacemaker cell lineage
of the sinoatrial node is specified in a mesoderm pop-
ulation that is separate from precursors of other cardiac
cell types. Our cell lineage studies in chick embryos have
also demonstrated that the segregation as well as differen-
tiation of coronary smooth muscle, fibroblast, and endothe-
lial cell lineages begins in an extracardiac tissue, the
proepicardium, prior to their entry to the heart. A separate
origin of coronary smooth muscle and endothelial cell
lineages have been confirmed by recent genetic studies of
mouse embryos. Thus, a precisely timed sequence of
development and integration of individual cardiac sub-
components is mediated through multiple genetic and
epigenetic programming during heart formation in higher
vertebrates.
[Supported in part by grants from NIH-NHLBI.]
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Antoon F.M. Moorman
Department of Anatomy, Embryology & Physiology,
Academic Medical Centre, Amsterdam, The Netherlands
a.f.moorman@amc.uva.nl
One of the most fascinating aspects in the formation of the
heart is the very early development of the electrical pattern-
ing as can be registered by the ECG, which is the registra-
tion of the rhythmic waves of depolarizing activity over the
cardiac muscle. In the mature heart, the conduction system
is held responsible for the rhythmic excitations and contrac-
tions. However, in chicken embryos a sinusoidal type of
ECG can already be derived from the linear heart tube stages
at about 2 days of development onward; and less than 1 day
later, when chamber formation has just been initiated, an
adult type of ECG can be monitored. The presence of an
adult type of ECG in these early embryonic hearts betrays
the development of fast-conducting chambers rather than the
presence of a conduction system. We now know that the
primary heart tube as seen in the early embryo contains the
precursors for the left ventricle only, or even less, whereas
the precursor cells for the remainder of the cardiac compo-
nents are continuously added to both the venous and arterial
pole of the heart tube during further development from a
single center of growth outside the heart. Therefore, it is
impossible that the straight heart tube contains the precur-
sors for the conduction system as rings separating the pur-
ported cardiac segments. While the primary heart tube is
growing by addition of cells, it does not show significant
cell proliferation until chamber differentiation and expan-
sion starts locally in the tube. The transcriptional repressors
Tbx2 and Tbx3 locally repress the chamber-specific pro-
gram of gene expression, by which these regions are
allowed to differentiate into the distinct components of the
conduction system. The cardiac building plan and the un-
derlying mechanisms of its formation are conserved from
fish to man.
Detailed reconstructions of the developmental patterns of
expression of Tbx3 during development in mouse and hu-
man have revealed that Tbx3 is expressed in those areas of
the heart tube that do not become chamber, i.e., in the sinu-
nodal region, internodal region, atrioventricular junction,
atrioventricular bundle, and bundle branches. These areas
comprise not only the conventional conduction system, but
also the highly controversial areas of the internodal region
and the entire atrioventricular junction. Also the (right)
ventricular outflow tract initially expresses these transcrip-
tional repressors, preventing it from chamber differentiation.
These observations provide an embryonic basis for why
some areas in the heart are more arrhythmogenic than other
regions.
Christoffels VM Moorman AFM (2009) Development of the cardiac
conduction system: Why are some regions of the heart more
arrhythmogenic than others? Circulation 2:195–207
Moorman AFM, Christoffels VM (2003) Cardiac chamber formation:
development, genes, and evolution. Physiol Rev 83:1223–1267
Sizarov A, Ya J, PhD, de Boer BA; Lamers WH, Christoffels VM,
Moorman AFM (2011) Formation of the building plan of the
human heart: morphogenesis, growth, and differentiation. Circu-
lation 123:1125–1135
van den Berg G, Abu-Issa R, de Boer BA, Hutson MR, de Boer
PAJ, Soufan AT, Ruijter JM, Kirby ML, van den Hoff MJB,
Moorman AFM (2009) A caudal proliferating growth center
contributes to both poles of the forming heart tube. Circ Res
104:179–188 (On-line interactive 3D PDF file available)
A1 2— Modulations of cardiomyocyte adhering
junctions during embryonic development and evolution
Sebastian Pieperhoff
Centre for Cardiovascular Science, Queen's Medical Re-
search Institute, University of Edinburgh, 47 Little France
Crescent, Edinburgh, EH16 4TJ, Scotland, UK
S.Pieperhoff@gmail.com
A detailed reinvestigation of adult mammalian cardiomyo-
cyte adhering junctions resulted in the discovery and defi-
nition of the composite junction (area composita). The
chosen terminology highlights the hybrid character of ad-
hering junctions connecting adult mammalian cardiomyo-
cytes, which are composed of typical desmosomal as well as
adherens junction components. Therefore, desmosomal pro-
teins are not restricted to relatively small desmosomes (as in
various epithelia), but are localized within the entire cardiac
intercalated disks.
Obviously, desmosomal proteins serve their function also in
adhering junctions anchoring myofibrillar actin bundles, the
composite junctions. This is of particular interest, as single
mutations in genes encoding for such desmosomal proteins
have been linked to the development of inherited forms of
cardiomyopathies, such as the arrhythmogenic right ventric-
ular cardiomyopathy/dysplasia (ARVC/D), often without
any signs of cutaneous disease involvement. In a subsequent
series of studies, I was then able to show that the formation
of composite junctions is a rather late event in both, mamma-
lian development and vertebrate evolution. Nascent cardio-
myocytes of early mammalian embryonic stages are for the
most part connected by relatively small intermediate filament
binding desmosomes and myofibrillar actin binding adherens
junctions (quite similar to adhering junctions connecting epi-
thelial cells). During late heart development (after birth),
single components of both structures become more and more
fused, and gradually relocated at the two poles within the
composite junctions of the mature mammalian ventricular
cardiomyocytes. Furthermore, results of studies on the adher-
ing junctions connecting cardiomyocytes of various lower
344 Cell Tissue Res (2012) 348:335–370vertebrate and invertebrate species will be briefly presented.
The findings described will be discussed in relation to cardio-
myopathy development and heart muscle regeneration.
A1 3— Endothelia of heart vessels: structure, molecules,
functions and dysfunctions
Maya Simionescu
Institute of Cellular Biology and Pathology "Nicolae
Simionescu", Bucharest, Romania
maya.simionescu@icbp.ro
The endothelial cell (EC) has earned the attention and re-
spect of biologists, who over the years discovered that far
from being a gratuitous cellophane-like layer, it has a key
role in body homeostasis and a large variety of pathologies.
Along the cardiovascular system, the structure of the EC
layer, which constitutes the boundary between the blood and
the tissues, varies as a function of the vessel or organ in
which they reside. The acquired innate heterogeneity con-
sisting of the distribution/number and organization of cav-
eolae, channels, type of intercellular junctions, and the
presence/absence of fenestrae, confers to ECs the ability to
adjust, sense, monitor, command, and modulate particular
local functions, as well as to respond to a variety of aggres-
sive factors. In physiological conditions, EC heart vessels
(and in many other locations) have a large array of consti-
tutive functions and the proper molecular configuration to
regulate the bidirectional receptor-mediated and receptor-
independent transcytosis of molecules between the plasma
and tissues, to execute endocytosis, to synthesize their own
basal lamina and extracellular matrix components, to guard
vascular tone (by balanced synthesis of vasoactive media-
tors PGI2, NO, EDHF, and endothelin), to regulate cellular
cholesterol and lipid homeostasis, and to administer haemo-
stasis (via vWf and PAI-1), signal transduction, and immu-
nity. At the molecular level, many of these functions are
implemented by EC caveolae, which are structurally and
functionally differentiated microdomains of the plasmalem-
ma endowed with receptors for LDL, HDL, albumin, trans-
ferrin, EGF, AGE, and insulin, as well as death receptors
(IL-1-R and P75-R).
Pathological conditions, i.e., exposure to cardiovascular risk
factors (hyperlipemia/hyperglycemia), lead to EC dysfunc-
tions, a key event in all stages of vascular diseases such as
atherosclerosis. The ECs sense the variations occurring in
the plasma or tissues, and initiate a focal response (in
arterial-susceptible areas) manifested firstly by adaptation/
modulation of their constitutive functions, such as increased
transcytosis of β-lipoproteins (βLp), and enhanced synthe-
sis of basal lamina and extracellular matrix components.
The increased transcytosis and the reduced efflux from the
intima, generate βLp alterations (oxidation, glycation, en-
zymatic modifications) and retention within the ECs' hyper-
plasic basal lamina as modified lipoproteins (mLp). The
latter, together with modifications of plasma homeostasis,
induce EC dysfunction (novel adhesion molecules, secretion
of chemokines, cytokines), which triggers a robust inflam-
matory reaction (recruitment and transvasation of immune
cells within the intima). All these alterations contribute to
atheroma formation and development in the heart vessels,
aorta, and other arterial segments. Ultimately, the insults
present inside and outside the vessel wall lead to EC injury,
apoptosis, and the ensuing vulnerable plaque rupture and
atherothrombosis. At the molecular level, the disease lies
within the EC, since vascular aggressors induce a cell or-
ganelle pathology manifested by amendments of membrane
components (new adhesion molecules), malfunction of cav-
eolae, and alterations in regulated transcytosis, and in the
functions of the endoplasmic reticulum, Golgi complex
(switch to a secretory phenotype), lysosomes (enzyme fail-
ure), and opening of intercellular junctions. The wealth of
data on the role of ECs in health and disease may constitute
together a complex discipline that includes endotheliology,
endotheliopathy, and endotheliotherapy.
[Work supported by grants from NIH-USA, European Com-
munity, Romanian Academy and Ministry of Education and
Research, Romania]
A1 4—Arrhythmogenic right ventricularcardiomyopathy;
a clinical and genetic perspective on desmosomes, desmin
and calcium
J. Peter van Tintelen
Department of (Clinical) Genetics, University Medical
Center Groningen, Groningen, The Netherlands
p.van.tintelen@medgen.umcg.nl
Arrhythmogenic right ventricular cardiomyopathy (ARVC)
is an inherited cardiomyopathy which usually presents with
palpitations or syncope due to ventricular tachyarrhythmias.
These arrhythmias may also underlie sudden death at rela-
tively young ages. The general hallmark of this disease is
(fibro-)fatty replacement of myocardial tissue, which con-
tributes to activation delay, reentry and subsequent ventric-
ular tachycardia. The areas of fibrofatty replacement are
mainly localized in the right ventricle (RV).
The diagnosis of ARVC is made using generally accepted
task force criteria. The initial criteria published in 1994
excluded left ventricular (LV) involvement. However, in
recent years it has become clear that serious LVinvolvement
can be found in ARVC as well. Recently, more left-
dominant forms of "ARVC" were observed (ALVC). Based
on these observations, the task force criteria for ARVC were
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maintaining specificity. Therefore, quantitative criteria were
proposed. Besides, LV involvement is no longer an exclu-
sion criterion, while the identification of a pathogenic mu-
tation for ARVC is incorporated in the new criteria.
The elucidation of genes underlying ARVC started in
2000 with the discovery that autosomal recessive Naxos
disease — a cardiocutaneous syndrome with ARVC and
skin and hair abnormalities — was due to a deletion in the
gene encoding plakoglobin. This is an important part of the
desmosome. This discovery paved the road for the discovery
of genes underlying autosomal dominantly inherited ARVC,
such as plakophilin 2 (PKP2), desmoglein 2, desmocollin 2,
and desmoplakin, all encoding proteins of the cardiac desmo-
some. Recently, desmin was added to this list. Because of the
clinical overlap between left sided "ARVC" and dilated car-
diomyopathy (DCM) a disease mainly involving the LV, we
recently screened the phospholamban gene (PLN), a calcium-
handling gene, in large DCM and ARVC cohorts from the
Netherlands. This led to the identification of a previously
described PLN mutation (R14del) in 10–15% of patients in
both groups. This mutation has previously been described in
DCM patients from other countries, and preliminary data
show that this might be a global founder mutation. Interest-
ingly, myocardial biopsies in PLN R14del ARVC patients
show absent or reduced plakoglobin at the intercalated disk
which has been suggested to be specific for ARVC, while the
PLN R14del DCM patients generally show normal amounts
of plakoglobin at the intercalated disk. These observations
shift the paradigm that ARVC is solely due to mutations in
desmosomal genes. The majority (>40 %) of ARVC patients
carry mutations in PKP2. If we consider proven familial cases
of ARVC, PKP2 mutations can be identified in up to 70 % of
families. This might suggest highly penetrant disease;
however, not all desmosomal gene mutation carriers de-
velop disease. This is also reflected by some recent large-
scale population-based studies from Finland and the Unit-
ed States. In these studies, 0.5 % of healthy controls
carried pathogenic mutations predisposing to ARVC, while
the prevalence of ARVC is believed to be 1:1000–1:5000.
The non-penetrance, clinical variability, and high preva-
lence of mutations in the general population hampers
tailor-made therapy and surveillance in mutation carriers,
who have a chance of dying suddenly, even in the absence
of abnormalities in cardiological evaluation.
A1 5— The changing spectrum of arrhythmogenic
cardiomyopathy
Cristina Basso
Department of Medico-Diagnostic Sciences and Special
Therapies, University of Padua Medical School, Padua, Italy
cristina.basso@unipd.it
Arrhythmogenic cardiomyopathy (AC) is a clinically and
genetically heterogeneous heart muscle disorder associated
with ventricular arrhythmias and even risk of sudden death.
The disease is heredo-familial, and mutations in desmo-
somal genes (plakoglobin, desmoplakin, plakophilin-2,
desmoglein-2, and desmocollin-2) have been identified in
up to 70 % of affected probands. Recent experimental
models confirm that this genetically determined cardiomy-
opathy develops after birth due to progressive myocardial
dystrophy. There is no single diagnostic "gold standard",
and in 2010 a revision of the diagnostic criteria, encompass-
ing familial, electrocardiographic, arrhythmic, morphofunc-
tional, and histopathologic findings, was made to improve
diagnostic sensitivity, but maintaining diagnostic specificity.
Quantitative parameters for imaging, tissue characterization,
ECG, and signal averaged ECG have been introduced, and
the identification of a pathogenic mutation in a first degree
relative has become a major criterion. Genotype–phenotype
correlations, including magnetic resonance and pathology
studies on heart specimens coming from heart transplant or
sudden death, are currently demonstrating that the spectrum
of the disease, usually referred to with the adjective "right
ventricular", is wider than initially thought, with the evidence
of biventricular or even isolated left ventricular forms, so that
it is increasingly identified simply as "arrhythmogenic car-
diomyopathy". Experimental cellular and animal models are
mandatory to try to gain an insight into the cascade of cellular
and molecular events leading from gene defect to myocardial
dystrophy in AC.
A1 6— Disease mechanisms in arrhythmogenic
cardiomyopathy: immunohistochemistry and beyond
Jeffrey E. Saffitz
Beth Israel Deaconess Medical Center/Harvard Medical
School, Boston, MA, USA
jsaffitz@bidmc.harvard.edu
Arrhythmogenic right ventricular cardiomyopathy (ARVC)
is a primary myocardial disorder characterized by an espe-
cially high incidence of ventricular arrhythmias and sudden
death. The identification of desmosomal gene mutations in
∼50 % of patients has led to the idea that ARVC is a disease
of abnormal cell–cell adhesion. However, recent insights
gained largely from studies of the human disease suggest a
greater degree of complexity. These insights include obser-
vations that: (1) plakoglobin (γ-catenin) is consistently
redistributed from desmosomes to intracellular/nuclear sites
in all forms of ARVC regardless of the underlying mutation,
(2) ARVC patients have elevated circulating cytokine levels
and myocardial production of cytokines, and (3) disease
flares often follow strenuous exercise in ARVC patients.
346 Cell Tissue Res (2012) 348:335–370These and other observations have helped us to propose an
overarching working model of the disease pathway in
ARVC. A central feature of this model is that desmosomal
mutations in ARVC result in abnormal responses to me-
chanical load which, in turn, promote subcellular redistribu-
tion of plakoglobin and induce cytokine expression.
Redistribution of plakoglobin from junctional to intracellu-
lar/nuclear pools sets the stage for altered canonical and
non-canonical Wnt signaling pathways with potential
changes in gene expression and perturbation of Ca
2+ ho-
meostasis. Cytokines locally expressed by injured cardiac
myocytes may promote development of fibrogenic and adi-
pogenic phenotypes in the myocardium through paracrine
effects on resident fibroblasts and progenitor cells. Altered
cellular biomechanics downstream of ARVC-causing muta-
tions also promote gap junction remodeling and cardiac
myocyte apoptosis. Collectively, these alterations lead to
cell injury, promote arrhythmogenesis, and contribute to
the pathology of the disease. We now have multiple lines
of evidence from studies of human disease and experimental
systems to support major aspects of this disease model and
to inform future studies. The hope is that insights gained
about mechanisms of cell injury and arrhythmogenesis in
ARVC may apply to more common forms of heart disease
and sudden cardiac death.
A1 7— Complex genetic behavior in arrhythmogenic
cardiomyopathy and the effect on disease mechanisms
Jeffrey A. Towbin
The Heart Institute and The Kindervelt–Samuel Kaplan
Professor and Chief, Pediatric Cardiology, Cincinnati Chil-
dren´s Hospital Medical Center, Cincinnati, OH, USA
jeffrey.towbin@cchmc.org
Objective: to define the genetic and mechanistic basis of
arrhythmogenic cardiomyopathy. Background: arrhythmo-
genic cardiomyopathy, previously known as arrhythmogenic
right ventricular dysplasia (ARVD) or arrhythmogenic right
ventricular cardiomyopathy (ARVC), is characterized by
myocardial fibrofatty replacement, ventricular dysfunction,
and arrhythmias associated with sudden death. Autosomal
dominant inheritance is most common, and reduced pene-
trance is the rule of thumb, but the underlying basis of low
penetrance is poorly understood. The causative genes identi-
fied to date are generally associated with desmosome func-
tion, the "final common pathway" of this disease. We
previously described compound and digenic heterozygosity
as a feature of this disorder which plays a role in the develop-
ment of the clinical phenotype and the severity of disease. We
have continued to perform genetic screening of 275 probands
and families with arrhythmogenic cardiomyopathy, and have
identifiedmutationsindesmosome-encodinggenes,aswellas
in genes that are not primarily involved in the desmosome but
disrupt the desmosome when mutated in at-risk domains. In
addition,wehavedevelopedanimalmodelsofseveralofthese
genes, and these models are providing insight into the biology
of the phenotype. These genes will be discussed, and the
animal models developed will also be described, along with
data on potential mechanisms of disease. Together, the data
presented will support the concepts that: (1) the complex
genetic basis of arrhythmogenic cardiomyopathy includes
reduced penetrance with compound and digenic heterozygos-
ity, (2) genes encoding non-desmosomal proteins result in
arrhythmogenic cardiomyopathy by disrupting desmosome
function by abnormal protein–protein interactions, and (3)
disturbed junctional cytoarchitecture in subjects and animals
with gene mutations that alter the desmosome confirms that
arrhythmogenic cardiomyopathy is a disease of the desmo-
some and cell junctions.
[Note: This topic was not orally presented because the
invited speaker could not attend the workshop for health
reasons]
A1 8— Naxos cardiocutaneous syndrome: recessive and
dominant forms
Adalena Tsatsopoulou, Nikos Protonotarios
Yannis Protonotarios Medical Center, Hora Naxos, 84300,
Greece
adalena@otenet.gr
Naxos cardiocutaneous syndrome associates arrhythmogenic
cardiomyopathy with hair and skin abnormalities. The orig-
inal description of the syndrome has been reported in 1986
for families originating from the Aegean island of Naxos as
a recessively inherited association of woolly hair, palmo-
plantar keratoderma and arrhythmogenic right ventricular
cardiomyopathy, given the name of "Naxos disease".
The disease phenotype initially presents with woolly hair
from infancy developing palmoplantar hyperkeratosis along
with the increasing use of hands and feet. The cardiomyop-
athy becomes clinically apparent during adolescence or
young adulthood, with ventricular arrhythmias, depolariza-
tion/repolarization changes in resting ECG, and structural/
functional abnormalities of the right as well as the left
ventricle, detected on two-dimensional echocardiography
and cardiac magnetic resonance. Symptomatic presentation
is with syncope, episodes of sustained ventricular tachycar-
dia, or even sudden death. Heart failure might appear at the
end stages of the disease, or earlier in cases with severe or
predominant left ventricular involvement, as in the Carvajal
variety of the Naxos cardiocutaneous syndrome. Cardiac
pathology reveals myocyte loss and fibrous or fibrofatty
replacement of myocardium, involving mostly subepicardial
Cell Tissue Res (2012) 348:335–370 347and mediomural layers. Up to now, families showing mem-
bers with Naxos disease have also been identified on other
Aegean islands. Moreover, cases from India, Ecuador, Italy,
Israel, Saudi Arabia, Turkey, United Kingdom, Spain, and
Finland have been reported with increasing frequency. They
mostly appear with autosomal recessive inheritance, but
autosomal dominant cases have also been described.
A 2-base-pair deletion mutation in plakoglobin, a key pro-
tein involved in cell–cell adhesion and signaling, was the
first identified gene to cause Naxos cardiocutaneous syn-
drome, and indicated an involvement of deficient cell–cell
adhesion in the pathogenesis of arrhythmogenic cardiomy-
opathy. Subsequently, mutations in the desmosomal plaque
protein desmoplakin (DSP) and recently in the transmem-
brane glycoprotein desmocollin-2 have been found to be
associated with recessive forms of Naxos cardiocutaneous
syndrome, while dominant or digenic DSP mutations have
been also related to the syndrome. The clinical appearance
of cardiomyopathy with respect to the predominance of
right or left ventricular involvement seems to be related to
the site of cell junction plaque where the causative mutation
is effective, i.e., mutations of desmoplakin truncating the
desmin-binding site of the molecule lead either to predom-
inant left ventricular involvement or to left dominant
arrhythmogenic cardiomyopathy overlapping clinically with
dilated cardiomyopathy (Carvajal syndrome). Dominant
forms usually show milder palmoplantar keratoderma, while
woolly hair is a constant finding in either dominant or
recessive cases. The associated skin defects apparent from
early infancy on enable the identification of individuals with
concealed heart disease when arrhythmogenic cardiomyop-
athy is in an "incubation" stage. Thus, a clinical "electrocar-
diographic/arrhythmic" phase can often be documented to
precede structural cardiomyopathy changes; molecular pa-
thology at this stage has also indicated remodeling of gap
junctions and electrical conduction.
A1 9— Inherited arrhythmia syndromes: clinical and
genetic management
Michael H. Gollob
Inherited Arrhythmia Clinic, Division of Cardiology and
Department of Cellular and Molecular Medicine, University
of Ottawa Heart Institute, Ottawa, Ontario, Canada
mgollob@ottawaheart.ca
Arrhythmogenic right ventricular cardiomyopathy (ARVC),
with an estimated prevalence of ARVC 1 per 5,000, is
characterized by fibrofatty replacement of myocardium. It
affects the right ventricle predominantly but may have left
ventricular involvement. ARVC can result in ventricular
arrhythmias, SCD, and right or biventricular dysfunction.
Often sporadic, the condition is familial in up to 50 % of
index cases. A pathogenetic theme for ARVC is the pres-
ence of mutations in genes encoding desmosomal proteins.
Desmosomes are a primary component of cell-adhesion
junctions, ensuring the structural and functional integrity
of cardiomyocytes. Mutations have been identified in genes
encoding for desmosomal proteins plakophilin-2 (PKP2),
desmoplakin (DSP), plakoglobin (JUP), desmocollin
(DSC2), and desmoglein (DSG2). A mutation in the gene
encoding a nondesmosomal protein (TMEM43)h a sb e e n
identified as the cause in a large cohort of related patients
in Newfoundland, Canada. The cellular function of the
tmem43 protein is still uncertain. The epidemiological situ-
ation of the "Newfoundland cluster" and the health manage-
ment consequences are disucssed. In addition, the
involvement of cardiac gap junctions in atrial fibrillations
is emphasized.
A2 0— Carvajal/Naxos syndrome secondary to
desmoplakin-dominantmutationisassociatedwithdilated
cardiomyopathy, woolly hair, palmoplantar keratoderma
and hypo/oligodontia
Lara Chalabreysse
1,2,5, Faiza Senni
1,5, Patrick Bruyère
3,
Brigitte Aime
1, Christophe Ollagnier
1, André Bozio
4,
Patrice Bouvagnet
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(1) Laboratoire Cardiogénétique, (2) Service de Pathologie,
(3) Service de Chirurgie Maxillo-faciale et Stomatologie, (4)
Service Cardiologie Pédiatrique, Hôpitaux de Lyon, Lyon,
France (5) Université de Lyon, F-69008 Lyon, France
patrice.bouvagnet@chu-lyon.fr
There is evidence that Carvajal (woolly hair, palmoplantar
keratoderma and dilated cardiomyopathy) and Naxos (same
hair and skin anomalies, with fibrofatty cardiomyocyte re-
placement in the right ventricle) syndromes are variable
expressions of the same syndrome secondary to mutations
in genes encoding proteins of the desmosome. Here we
report an additional sign that might be helpful to cardiolo-
gists in establishing the diagnosis. The proband had three
episodes (at age 15, 16 and 27) of chest pain with transient
ST elevation in leads V3–V4 and mild rise of troponin. He
had LV enlargement (diastolic diameter 64 mm) with nor-
mokinetics and no coronary anomalies. He had good adap-
tation to physical activity, but numerous premature beats
disappearing during physical stress. He had palmoplantar
keratoderma, woolly hair, and was missing the left mandib-
ular 2nd molar and all 3rd molars. A younger brother had
two fainting episodes when he was 17. He had incomplete
RBBB and dilated left ventricle with normokinetics. Four
years later, he had shortness of breath with LVat 70 mm and
EF at 20 %. He had runs of ventricular tachycardia. He
348 Cell Tissue Res (2012) 348:335–370received a heart graft. His heart had enlarged ventricles with
fibrofatty replacement in the right ventricle. He had palmo-
plantar keratoderma, woolly hair, and marked oligodontia
with only four permanent molars and several persisting
primary teeth. The father, who experienced several fainting
spells, had also a dilated cardiomyopathy with the same
skin, hair, and teeth anomalies. The desmoplakin (DSP)
and plakoglobin (JUP) genes were screened for mutations,
and a single heterozygous mutation was found in the DSP
gene: p.Ser597Leu. This residue is conserved across verte-
brates and absent from 100 controls. The mutation was
found in the two brothers and their father, but absent from
all other family members. Conclusion: heterozygous mis-
sense mutation in the DSP gene may result in chest pain,
fainting episodes, and dilated cardiomyopathy. The associ-
ation of woolly hair, palmoplantar keratoderma, and/or oli-
godontia may help in establishing the diagnosis of Carvajal/
Naxos disease.
A2 1— Reduction of preload: a pathophysiological
approach to therapy in arrhythmogenic right ventricular
cardiomyopathy?
Paulus Kirchhof
Birmingham University, UK, and University Hospital
Münster, Germany
KirchhP@ukmuenster.de
The observations and thoughts reported here have been
published in JACC (1).
Arrhythmogenic right ventricular cardiomyopathy
(ARVC) is an important cause of sudden death in the
young (2–6). Despite progress in the prevention of sud-
d e nc a r d i a cd e a t hi nA R V Cp a t i e n t sb ya n t i a r r h y t h m i c
drugs and implanted defibrillators (7–8), there is no
treatment available that slows or prevents development
of ARVC (2, 9–10).
Mutations in genes encoding for mechanical cell–cell con-
tact proteins are found in ARVC patients (11–17). Trans-
genic mouse models have verified the biological relevance
of mechanical cell–cell contact dysfunction for ARVC. The
disease develops in mice with heterozygous deletion of
plakoglobin (18), heterozygous deletion of desmoplakin
(19), and transgenic expression of desmoglein (20). Recent
analyses in myocardial tissue from ARVC patients suggest
that reduced immuno-histological plakoglobin light intensi-
ty may be a sensitive and specific marker for ARVC in
patients (5). Hence, genetic defects in the mechanical cell–
cell contacts appear to be the underlying pathophysiological
principle of ARVC. Endurance training, especially when
performed at a competitive level, may accelerate the mani-
festation of ARVC in susceptible individuals (21–22).
Likewise, endurance training accelerates the development
of ARVC in heterozygous plakoglobin-deficient mice
(plako
+/-, [18]), suggesting that chronically increased vol-
ume load may contribute to development of ARVC in sus-
ceptible patients. We therefore tested whether reducing
ventricular pressure and volume load can prevent or slow
training-induced development of ARVC.
Objective: We used a murine model of arrhythmogenic
right ventricular cardiomyopathy (ARVC) to test whether
reducing ventricular load prevents or slows development of
this cardiomyopathy.
Methods: Littermate pairs of heterozygous plakoglobin-
deficient mice (plako
+/-) and wild-type (WT) littermates
underwent 7 weeks of endurance training (daily swimming).
Mice were randomized to blinded load-reducing therapy
(furosemide and nitrates) or placebo.
Results: Therapy prevented training-induced right ventric-
ular (RV) enlargement in plako
+/- mice (RV volume: un-
treated plako
+/- 136±5μl; treated plako
+/- 78 ± 5 μl; WT
81 ± 5 μl; p < 0.01 for untreated vs WT and untreated vs
treated; mean ± SEM). In isolated, Langendorff-perfused
hearts, ventricular tachycardias (VT) were more often in-
duced in untreated plako
+/- hearts (15/25) than in treated
plako
+/- hearts (5/19) or in wild-type hearts (6/21, both
p < 0.05). VT occurred due to macro-reentry and decreased
RV longitudinal conduction velocity in untreated but not in
treated plako
+/- mice (p < 0.01 for untreated vs WT and
untreated vs treated). Myocardial concentration of phos-
phorylated connexin43 was lower in plako
+/- hearts with
VTs compared to hearts without VTs, and was reduced in
untreated plako
+/- compared to WT (both p < 0.05). Plako
+/-
hearts showed reduced myocardial plakoglobin concentra-
tion, while β-catenin and N-cadherin concentration was not
changed.
Conclusions: Load-reducing therapy prevents development
of ARVC in plako
+/- mice, and may provide a simple ap-
proach to preventing disease progression in ARVC patients.
This potential effect of preload reduction should be tested in
a controlled clinical trial.
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A2 2— Sudden death in athletes
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Sudden death in athletes occurs due to hidden cardiac dis-
orders which, often during effort, may jeopardize heart
electrical stability, triggering ventricular fibrillation. Apart
from rare conditions of ion channel diseases in a structurally
normal heart, in which the disorder may be detected simply
by basal or stress test 12 lead ECG, the anomalies at risk of
sudden death may affect the aorta (Marfan syndrome), the
coronary arteries (congenital anomalies, premature athero-
sclerosis), the myocardium (hypertrophic and arrhythmo-
genic cardiomyopathies), the valves (bicuspid aortic valve,
mitral valve prolapse) and the conduction system (preexci-
tation syndromes). These disorders are for the most part
detectable by ECG and/or echo. The employment of these
methods in screening tests before competitions or other
athletic meetings can help to identify masked anomalies
and should play a major role in early diagnosis, risk strati-
fication and prevention of sudden death.
A2 3— Wnt-Ca
2+ as an integrator of differentiation
signaling in the heart
Calum A. MacRae
Cardiovascular Division, Brigham & Women´s Hospital,
Boston, MA, USA
camacrae@bics.bwh.harvard.edu
Intercellular junctions have been directly implicated in the
pathobiology of several forms of human cardiomyopathy
through human genetic studies. The downstream mecha-
nisms of the junctional perturbations remain obscure, but to
date abnormalities of mechanical and electrochemical sig-
naling have been identified. We have used the zebrafish to
model multiple aspects of junctional biology during normal
and pathological cardiogenesis.
In the first instance, we focused on developing techniques to
characterize the dynamics of intercellular coupling during
350 Cell Tissue Res (2012) 348:335–370normal cardiac development. High-resolution optical volt-
age mapping, Fura-2 calcium imaging and traditional im-
munohistochemical techniques were combined to define
cardiomyocyte differentiation and cell coupling at multiple
stages from the linear heart tube stage through to 120hpf,
when the zebrafish heart is highly representative of adult
human cardiac physiology. The structural and functional
remodeling of junctions is coupled with cytoskeletal and
membrane lipid remodeling which we are also beginning
to characterize. We have identified remarkable plasticity of
cardiomyocyte coupling throughout development, with dis-
tinctive regional variation in the complexity and strength of
coupling. These data demonstrate that the myocardial syn-
cytium is not uniform, but rather consists of a complex
series of local networks. Exploration of a series of zebrafish
mutants has identified roles for pathways implicated in
synaptogenesis in the formation of specific regional cou-
pling networks.
Interestingly, non-canonical Wnt signals polarize ventricular
myocardial structure and function, but do not perturb the
major ventricular cardiomyocyte networks. We were unable
to detect any role for traditional planar cell polarity path-
ways in the Wnt-associated polarity changes, but identified
as p e c i f i cr o l ef o rt h eL - t y p ec a l c i u mc h a n n e li nt h e s e
cellular and physiologic rearrangements. This novel limb
of Wnt–calcium signaling directly connects extracellular
and intracellular compartments, and may serve to integrate
canonical and non-canonical Wnt pathways.
Given the role of desmosomal proteins in human cardiomyop-
athy, we established and validated multiple zebrafish lines
expressing dominant negative mutants implicated in disease.
Using a range of reporter lines, and existing zebrafish Wnt
signaling mutants, there is evidence for both canonical and
non-canonical Wnt pathway abnormalities in desmosomal car-
diomyopathies. We have used one of our lines expressing a
mutant plakoglobin line to develop a high-throughput screen
forgeneticandchemicalsuppressorsofdesmosomalpathology.
This line develops a cardiomyopathy with extensive morpho-
logic and physiologic homology to ARVC, and is associated
with reduced survival, sudden death and congestive heart fail-
ure. We are currently evaluating novel Wnt–calcium pathway
members identified in zebrafish, and screening chemical librar-
ies for novel modulators of desmosomal disease pathways for
use as pathway probes, diagnostics or therapeutic leads.
A2 4— Clinical challenges in ARVC/D: a United States
perspective
Hugh M. Calkins
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The Johns Hopkins ARVD Program was initiated in 1999
w i t ht h eg o a lo ff u r t h e r i n gr e s e a r c ho nA R V Da n da l s o
providing clinical care for patients with known or suspected
ARVD. During the past 10 years, we have evaluated more
than 1,000 patients for this condition. The purpose of this
presentation will be to present our clinical experience with
ARVD and to focus on what we perceive to be the more
vital unanswered questions. Particular emphasis will be
placed on describing the remarkable heterogeneity of the
clinical manifestations of the disease. Our aim will be to
provide a clinical context for the remarkable advances in
basic research that will be discussed at this meeting.
A2 5— The molecular biology and genetics of blood
pressure and its regulation
John J. Mullins
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Mammalianbloodpressureisregulatedbyamyriadoffactors,
many of which have been identified by classical biochemical
and physiology experimentation, whilst others have emerged
through genetic studies in both human populations and rodent
models. The advent of genetic manipulation in vivo has facil-
itated the investigation of mechanisms underlying inherited
forms of hypertension and the cell biology and physiology of
altered blood pressure homeostasis.
Renin is a critical component of a classical renin–angioten-
sin–aldosterone system (RAAS), which regulates long-term
mammalian blood pressure. We have shown that a threshold
level of expression of the renin is an essential determinant of
the morphology and function of the renal juxtaglomerular
cells and of the structure of the anatomically and function-
ally related macula densa cells. In genetic rescue experi-
ments, we have shown that human renin expression in mice
lacking endogenous renin1 enzyme rescues the JG cell
deficit but is not sufficient, in isolation, to restore normal
macula densa structure.
Two of the key effectors of the classic RAAS are angioten-
sin II (Ang II) and aldosterone. Whilst much attention has
been paid to the actions of Ang II in regulating blood
pressure, the dysregulation of the aldosterone axis is also
known to lead to profound physiological and pathophysio-
logical consequences, including a marked elevation of blood
pressure. Aldosterone is not the sole activator of MR in
vivo, and glucocoticoids are known to bind to MR with
similar efficiency to that of aldosterone. The relative abun-
dance of glucocorticoids in the plasma provides the poten-
tial for substantive glucocorticoid-mediated activation of
MR. Under normal circumstances, such activation is
Cell Tissue Res (2012) 348:335–370 351prevented by the enzyme 11 beta hydroxysterioid dehy-
dogenase type 2 (11 beta HSDII), which acts locally to
inactivate glucocorticoids and thereby prevents their ac-
cess to MR, resulting in the apparent specificity of
aldosterone action. Lack of 11 beta HSDII activity in
humans results in the syndrome of apparent mineralo-
corticoid excess (SAME), a severe hypertensive disorder
with characteristic electrolyte imbalance and a poor
prognosis. We have established a transgenic mouse
model of SAME which recapitulates all the key features
of the human condition and facilitates investigation of
the underlying mechanism of the syndrome and the
consequences of chronic reduction in the expression of
this critical "gate-keeper" enzyme. Current developments
and potential pitfalls of the use of genetic modification
will be discussed, with a focus on its use in investigat-
ing blood pressure homeostasis.
A2 6— The specific molecular ensembles of the
junctions connecting mesenchymally-derived tumor
cells, including cardiac myxomata: the coming and
going of plakophilin-2
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In contrast to the advanced state of the molecular character-
ization of the junctions connecting epithelial cells, i.e., the
intermediate-sized filament (IF)-anchoring desmosomes
(maculaeadhaerentes)andthemicrofilament-associatedadhe-
rens junctions (AJs), knowledge of the molecular components
of the AJs that connect the diverse types of mesenchymally-
derived cells — normal or malignantly transformed — is still
verylimited.Therefore, wehavebeguntostudy the molecular
composition and the assembly mechanisms of the AJs con-
necting the cells of mesenchymally-derived tissues and soft-
tissue tumors. In a systematic study to elucidate the molecular
composition of the AJs that connect non-epithelial cells, we
haveidentifiedaseriesofnovelandfrequentcelltype-specific
molecular AJ ensembles, some of which represent unexpect-
edly new categories of junctional assemblies, including mol-
ecules hitherto only known as major components of
desmosomes in epithelial and carcinomatous cells. Using
biochemical and immunocytochemical as well as electron
microscopical methods, we have identified a category of AJs
connecting diverse normal and proliferatively-transformed,
mesenchymally-derived cells, which in addition to N-
cadherin and/or cadherin-11 contain a dense cytoplasmic
plaque formed by a- and b-catenin, plakoglobin as well as
proteins p120 and p0071, but also major amounts of the
desmosomal plaque proteins plakophilins-2 (Pkp2) and/or -3
(Pkp3). Such mixed type AJs have been discovered in certain
proliferatively active normal cell culture lines, as well
as in malignantly transformed cells (Rickelt et al. 2009).
In particular, we have found this novel AJ type in
diverse kinds of human soft-tissue tumors, including
rhabdomyosarcomas, and remarkably consistent in car-
diac myxomata (without exception in all 38 cases ex-
amined so far; Rickelt et al. 2010). The specific
correlation of the advent of such Pkp2-positive AJs with
the proliferative state of the given cells is essentially
well demonstrable with the interstitial cells of the car-
diac valves (Barth et al. 2009). The possible diagnostic
value of Pkp2 in tumor diagnosis is obvious.
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A2 7— N-cadherin antagonists as oncology therapeutics
Orest W. Blaschuk
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N-cadherin is a cell adhesion molecule (for review, see
Hulpiau and van Roy 2008) that plays a pivotal role in
promoting blood vessel formation and stability (for review,
see Blaschuk and Devemy 2009). Both of these processes
are essential for tumor growth (for review, see Folkman
2007; Naumov et al. 2008). Initially, I will discuss the
discovery and development of N-cadherin antagonists.
These antagonists consist of three series of compounds:
linear peptides (Blaschuk et al. 1990), cyclic peptides
(Williamsetal. 2000)andpeptidomimetics(Gouretal.2007).
In particular, I will focus on the effects of these antagonists on
endothelial cell adhesion (Erez et al. 2004). Secondly, I will
352 Cell Tissue Res (2012) 348:335–370discuss pre-clinical (Shintani et al. 2008; Augustine et al.
2008) and clinical studies (Beasley et al. 2009; Perotti et al.
2009) designed to ascertain the effects of the N-cadherin
antagonist, ADH-1 (a synthetic cyclic pentapeptide) on tumor
growth. Collectively, the data suggest that N-cadherin antag-
onists might be useful as anti-cancer agents.
Augustine CK, Yoshimoto Y, Gupt M, Zipfel PA, Selim MA, Febbo P,
Pendergast AM, Peters WP, Tyler DS (2008) Targeting N-
cadherin enhances antitumor activity of cytotoxic therapies in
melanoma treatment. Cancer Res 68:3777–3784
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A2 8— The cardiac fibroblast: phenotypes, functions
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Cardiac fibroblasts (CF) are the most prevalent cell
type in the mammalian heart, yet until recent years
their role in regulating myocardial function and remod-
elling has been largely overlooked in favour of the
cardiac muscle cells, cardiomyocytes. The critical role
of CF in maintaining myocardial homeostasis in the
healthy heart is underscored by the need to provide
structure, function, and connectivity for all the myo-
cardial cell types. CF therefore play key roles in reg-
ulating not only normal myocardial function but also
during adverse remodelling that occurs with hyperten-
sion, myocardial infarction (MI) and heart failure (HF).
Through cell–cell interaction and secretion of growth
factors, cardiomyocyte function is directly modulated
by CF and vice versa. During the myocardial remod-
elling that follows MI and in HF progression, CF
undergo activation to a myofibroblast phenotype,
expressing contractile proteins such as α-SMA and
modulating their function through increased prolifera-
tive, migratory, and secretory properties.
In the remodelling heart, CF are functionally responsive
to the elevated levels of proinflammatory cytokines such
as TNF-α and interleukins, vasoactive peptides (e.g.,
angiotensin II, endothelin-1) and hormones (e.g., nor-
adrenaline). Such effects include changes in cell prolif-
eration, cell migration, extracellular matrix turnover, and
secretion of bioactive molecules including cytokines,
peptides, and growth factors. Although these changes in
function are an important adaptive response to myocar-
dial injury, in the long term they lead to adverse remod-
elling and heart failure. Many commonly prescribed
cardiovascular therapies (for example ACE inhibitors,
beta-blockers, and statins) also exert pleiotropic effects
on cardiac fibroblasts that may explain some of their
benefits in the remodelling heart. In addition, as the
importance of CF emerges and our understanding broad-
ens, modulation of their phenotype and function may
provide a worthwhile goal in the quest for novel, targeted
therapeutics.
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"The heart is a muscle. Muscle is meat. Meat consists of myo-
cytes. If you understand myocytes, you understand the heart." If
this was our conceptual approach to exploring cardiac structure–
functionrelationships andelectro-mechanicalactivity,wewould
be bound to fail. The heart contains more non-myocytes than
muscle cells (Vliegen et al. 1991), and the majorityof the former
are referred to as fibroblasts (Adler et al. 1981). The traditional
view offibroblasts is dominated by regarding them as 'obstacles'
(from blocking conduction in vivo, to overgrowing cell cultures
in vitro). This perception is shifting, however, to give way to an
increasingly integrative appreciation of the relevance of fibro-
blasts for proper function of cardiac myocytes (Camelliti et al.
2005). This trend is evident from increased publication numbers
on the topic, as can be illustrated by a PubMed search for
'(fibroblast) AND (heart OR cardiac)': out of 8,000+ entries
returned for the term, more than half have been published in
the past 10 years. As is evident from these numbers, cardiac
myocyte–fibroblast interactions are a huge field. This presenta-
tion will focus, therefore, on a small aspect of those interactions:
electrical cross-talk between the heterogeneous cell populations.
A brief introduction of terms and concepts will be followed by a
review of insight from 'wet' experimental and 'dry' computation-
al basic research, a consideration of clinical correlates, an as-
sessment of underlying molecular substrates for electrical
cell–cell interaction, and an outlook that considers current
technical and conceptual limitations, as well as possible sol-
utions—regrettably,however,withoutansweringthe'friendor
foe?' question (Baudino et al. 2006).
Adler CP, Ringlage WP, Böhm N (1981) DNS-Gehalt und Zellzahl in
Herz und Leber von Kindern. Pathol Res Pract 172:25–41
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terisation of cardiac fibroblasts. Cardiovasc Res 65:40–51
Vliegen HW, van der Laarse A, Cornelisse CJ, Eulderink F (1991)
Myocardial changes in pressure overload-induced left ventricular
hypertrophy: A study on tissue composition, polyploidization and
multinucleation. Eur Heart J 12:488–494
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We have recently described a novel type of interstitial cells
— telocytes (TC) — in several cavitary and non-cavitary
organs, from humans and mammals (Popescu and Faussone-
Pellegrini 2010). TC were found in all the three concentric
layers of heart: epi-, myo- and endocardium (see www.
telocytes.com). Their presence was repeatedly confirmed
and, moreover, a "map" of TC localization in heart was
established (Liu et al. 2011). TC have a small body, but
specific (unique) prolongations, that we named telopodes
(Tp). Therefore, the simplest definition of telocytes (TC) is:
cells with Tp. Tp are characterized by: (a) number (1–5,
frequently 2–3), (b) length (several tens up to hundreds of
micrometers), (c) moniliform aspect: alternation of dilated
segments (podoms) and thin segments (podomers — less
than 200 nm thickness, below the resolving power of light
microscopy, explaining the fact that TC were overlooked so
far), (d) podoms accommodating mitochondria, endoplas-
mic reticulum (ER) and caveolae — the so-called “Ca
2+
uptake/release units”, and (e) dichotomous branching pat-
tern, making a 3D network, a labyrinthine system with
particular ultrastructural homo- and hetero-cellular junc-
tions. It is worthy of note that TC and especially Tp release
microvesicles (mean diameter of 180 nm), sending macro-
molecular signals to neigboring cells and eventually modi-
fying their transcriptional activity.
The immunophenotype of TC includes mainly CD 34,
CD117/c-Kit, and vimentin, but also caveolin-1, CD44,
NOS-2, desmin, cadherin-11, PDGF-R beta and so on. Al-
though for the time being, electron microscopy remains the
election method to precisely identify TC, double-positive
immunostaining with CD34/c-Kit (mainly for cell body) or
CD34/vimentin (mainly for Tp) also represents a useful
marker for TC. MicroRNA profile of TC is characterized
by the absence of miRs 1, 133a, 208a, specific for cardio-
myocytes, but the distinct presence of miR 608. Micro
RNAs 126-3p, 151-5p, and 193 are differentially expressed
by TC in comparison with other interstitial cells (e.g., fibro-
blasts), as resulted from laser capture microdissection. TC
contain measurable quantities of angiogenic microRNAs
(e.g., let-7e, 10a, 21, 27b, 100, 130a, 143, 155, 503) (Man-
ole et al. 2011). It is worthy of mention that TC have a
diverse paracrine secretion (VEGF, NO, IL6, chemokines),
as suggested by immunohistochemistry and confirmed by
SELDI-TOF mass spectrometry and xMAP technology
(Luminex) for TC in tissue culture. In cell cultures, when
compared to fibroblasts (3T3), TC produced 8 times more
IL6 and 3 times more VEGF respectively. Transmission
electron microscopy and electron tomography revealed
complex junctions between TC and cardiomyocytes, as well
354 Cell Tissue Res (2012) 348:335–370as nanostructural junctions between TC and resident pro-
genitor cells, at the level of epicardial stem cell niches
(Gherghiceanu and Popescu 2010, 2011). It is worthy of
note that close contacts between TC and putative pro-
genitor cells were also found at the level of interstitial
stem cell niches in lungs (Popescu et al. 2011), as well
as in skeletal muscle (Popescu et al. 2011). TC, with
their Tp, surround cardiac progenitors or precursors to
guide them to form the coherent 3D myocardial archi-
tecture. Apparently, Tp provide “tracks” for the sliding
of cardiomyocyte precursors in their development and
integration as working cardiomyocytes.
In conclusion, in the adult mammalian heart, TC together
with resident stem cells and cardiomyocyte progenitor sus-
tain a continuous cardiac renewal process, and might be
key players in repairing the damaged heart. TC “nurse”
the progenitor cells in stem cell niches. The tandem TC–
stem cells could be a better option for therapy rather than
stem cells alone. Last but not least, TC are directly
(physically) and indirectly(chemically)involvedinneoangio-
genesis after myocardial infarction.
Gherghiceanu M, Popescu LM (2010) Cardiomyocyte precursors
and telocytes in epicardial stem cell niche: electron micro-
scope images. J Cell Mol Med 14:871–877
Gherghiceanu M, Popescu LM (2011) Heterocellular communication
in the heart: electron tomography of telocyte–myocyte junctions. J
Cell Mol Med 15:1005–1011
Liu JJ, Shen XT, Zheng X, Li Z, Wang J, Q XF (2011) Distribution of
telocytes in the rat heart. J Clin Rehabil Tissue Eng Res 15:3546–
3548
Manole CG, Cismasiu V, Gherghiceanu M, Popescu LM (2011) Ex-
perimental acute myocardial infarction: telocytes involvment in
neo-angiogenesis. J Cell Mol Med 15:2284–2296
Popescu LM, Faussone-Pellegrini MS (2010) Telocytes – a case of
serendipity: the winding way from interstitial cells of Cajal (ICC),
via interstitial Cajal-like cells (ICLC) to telocytes. J Cell Mol Med
14:729–740
Popescu LM, Gherghiceanu M, Suciu LC, Manole CG, Hinescu ME
(2011) Telocytes and putative stem cells in the lungs: elec-
tron microscopy, electron tomography and laser scanning
microscopy. Cell Tissue Res 345:391–403
Popescu LM, Manole E, Serboiu CS, Manole CG, Suciu LC,
Gherghiceanu M., Popescu BO (2011) Identification of telo-
cytes in skeletal muscle interstitium: implication for muscle
regeneration. J Cell Mol Med 15:1379–1392
A3 1— Periostin/filamin A: a candidate central
regulatory mechanism for valvular fibrogenesis and
matrix compaction
Roger Markwald, Russell Norris, Suniti Misra, Shibnath
Ghatak
Cardiovascular Developmental Biology Center, Department
of Regenerative Medicine, Medical University of South
Carolina, Charleston, SC, USA
markwald@musc.edu
Periostin (PN) is a fasciclin-related protein secreted by
prevalvular primordial mesenchyme of the developing
ventricular inlets and outlets. It is also expressed by
interstitial cells of the embryonic and adult ventricular
myocardium. We have previously shown that PN pro-
motes cell autonomous, fibrogenic differentiation and
the compaction of a collagenous matrix into mature
valve leaflets and cusps. Loss of periostin inhibits dif-
ferentiation into fibroblast lineages, collagen secretion
and matrix compaction, resulting in abnormally elongat-
ed, myxomatous valves with potential for prolapse and
regurgitation. With respect to mechanism(s), PN, as a
matricellular protein, may promote matrix compaction
and maturation by directly b i n d i n gt oc o l l a g e n( t h e r e b y
increasing cross-linking) or indirectly by binding to
integrins and potentially initiating signaling changes in
cytoskeleton organization that modify the contractile
forces that mediate matrix compaction. To test the latter
mechanism, we initiated signaling studies and a 3D
assay to determine if PN promoted matrix compaction
by activating integrin-associated signaling pathways, and
if such activation included phosphorylation of A
(FLNA), an actin binding, cytoskeletal protein specifi-
cally expressed in cardiac valve and interstitial fibro-
blasts. IP data, Western blots and immunostaining
indicated that PN binding to 3 integrin specifically
promoted phosphorylation of FLNA (a.a. 2152) by ac-
tivating cdc42 and pak1 kinases, and that the 2152
phosphorylation site of FLNA occurred near two point
mutations (P673Q and G228R) found in patients with
degenerative (myxomatous) valve diseases. Silencing or
deleting periostin inhibited 2152 FLNA phosphorylation,
which correlated with reduced potential of prevalvular
interstitial cells (also ventricular fibroblasts) to compact
collagen gels. Introducing the P673Q and G228R muta-
tions into mouse prevalvular mesenchyme inhibited both
collagen compaction and the phosphorylation of FLNA
(2152). Fibroblasts from patients with P673Q and
G228R mutations or mouse fibroblasts expressing one
or more of these mutations or silencing vectors for PN
also exhibited reduced binding of an enzyme — trans-
glutaminase 2 (TG2) — which covalently links seroto-
nin to FLNA. Pharmacologically or genetically
inhibiting "serotonylation" of FLNA strongly suppressed
matrix compaction and valve maturation. Together, these
findings indicate that PN can regulate valvulogenesis
and matrix maturation by triggering integrin-dependent
signaling mechanisms that target FLNA and its potential
to generate cytoskeletal contractile forces through an
interaction with TG2 and serotonin.
[Supported by NHLBI, AHA, NCRR and Leducq Mitral
Transatlantic Network.]
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Elaine E. Wirrig, Jonathan D. Cheek, Santanu Chakraborty,
Christina M. Alfieri, Robert B. Hinton,
Katherine E. Yutzey
The Heart Institute, Cincinnati Children's Hospital Medical
Center, Cincinnati, OH, USA
katherine.yutzey@cchmc.org
Studies of human explanted aortic valves and mouse models
were used to define molecular, cellular, and morphogenetic fea-
tures of heart valve disease progression. In human diseased aortic
valves, valvular interstitial cell (VIC) activation, extracellular
matrix (ECM) disorganization, and induction of markers of valve
mesenchymal and cartilage progenitor cells are observed in both
pediatric and adult diseased aortic valves. In contrast to calcific
valve disease in adults, pediatric diseased aortic valves do not
calcify,andexpression ofosteogenicmarkersisapparentin adult,
but not pediatric, diseased aortic valves. Interestingly, phospho-
Smad1/5/8 also is increased in adult calcified valves, suggesting
that BMP signaling contributes to heart valve calcification. Os-
teogenesis imperfecta murine (Oim) mice have a mutation in
Col1a2 that affects collagen fibrillogenesis and leads to bone
fragility. The valves of Oim/Oim mice have decreased collagen
and increased proteoglycan composition with leaflet thickening.
In addition, the Oim/Oim mice have increased expression of
valve and cartilage progenitor markers, consistent with increased
proteoglycan composition and absence of calcification.
Klotho-null mice are a model for premature aging, and exhibit
calcified nodules in aortic valves in the absence of leaflet thick-
ening or ECM disorganization. Klotho-null aortic valves have
increased expression of the transcription factor Runx2, consis-
tent with the calcified phenotype, in addition to increased ex-
pression of cartilage marker genes. Together, these findings
demonstrate specific molecular indicators of aortic valve disease
progression, which could lead to identification of early disease
markers and the development of therapeutic interventions.
A3 3— Next generation sequencing in ARVC mutation
detection and new genes for desmosomal-like disease
David P. Kelsell
The Blizard Institute, Barts and The London School of
Medicine and Dentistry, Queen Mary University of London,
London, E1 4AT, UK
d.p.kelsell@qmul.ac.uk
The importance of desmosomes for maintenance of the
strength and flexibility of these tissues is highlighted by
natural and in vitro engineered mutations in desmosomal
genes, which compromise skin or heart and in some instan-
ces both. Indeed, desmosomal gene mutations account for
45–50 % of cases of arrhythmogenic right ventricular car-
diomyopathy (ARVC). ARVC is a disease of ventricular
myocardium, which on macroscopic histological examination
reveals ventricular dilatation, thinning of affected myocardi-
um, and areas of scarring. Detailed genetic sequencing has
now identified both heterozygous and mutations in all five
major proteins within the desmosome. The current detection
rate of pathogenic mutations in non-syndromic ARVC is 45–
50%,withmutationsmostcommonlyseeninPKP-2andleast
frequently seen in PG. In this presentation, the role of targeted
capture followed by next-generation sequencing in ARVC
mutation identification will be described. In an initial study
of 12 patients clinically diagnosed with ARVC but not yet
genotypically characterised, nine desmosome protein muta-
tions were identified, of which seven were novel.
In addition, we have used next-generation sequencing to
discover new genes linked with the regulation of des-
mosome function. For example, we studied two siblings
with autosomal recessive neonatal inflammatory skin
and bowel lesions. The affected female died suddenly
aged 12 of parvovirus B19 myocarditis, and her brother
has mild cardiomyopathy. We have identified the first
human loss-of-function mutation in ADAM17 [encoding
a disintegrin and metalloproteinase 17, ADAM17, also
called 'tumor necrosis factor (TACE)'-converting en-
zyme)] as the likely underlying cause of this syndrome
(Blaydon, Biancheri et al. 2011). Functional studies
revealed defective DSG2 processing. We have also re-
cently identified loss-of-function mutations in the gene
for protease inhibitor cystatin A (CSTA) as the under-
lying genetic cause of exfoliative ichthyosis (Blaydon,
Nitoiu et al. 2011).
Electron microscopy of patient skin biopsies revealed that
the level of skin peeling occurs between the basal and
suprabasal layers in these patients. In addition, in vitro
modelling suggests that in the absence of cystatin A protein,
there is a cell–cell adhesion defect in human keratinocytes
that is particularly prominent when cells are subject to
mechanical stress. This is the first evidence of a key role for
a protease inhibitor in epidermal adhesion within the lower
layers of the human epidermis. Further functional studies
describing the effect of ADAM17 and CSTA gene mutations
in keratinocytes and desmosome biology will be described.
[The two papers below were in press at the time of Heidelberg Heart II.]
Blaydon DC, Biancheri P, Di WL, Plagnol Vet al (2011) Inflammatory
skin and bowel disease linked to ADAM17 deletion.N Engl J Med
365:1502–1508
Blaydon DC, Nitoiu D, Eckl KM, Cabral RM et al (2011) Mutations in
CSTA, encoding Cystatin A, underlie exfoliative ichthyosis and
reveal a role for this protease inhibitor in cell–cell adhesion. Am J
Hum Genet 89(4):564–571
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6JH, UK
m.yacoub@imperial.ac.uk
Until recently, heart valves were thought of as passive struc-
tures, which are driven by haemodynamic events, with the sole
function of guaranteeing unidirectional flow with minimal or
no obstruction. Recent evidence has shown that heart valves
perform extremely sophisticated functions which depend on
their viability and the specific characteristics of their compo-
nent parts, at tissue, cellular, and molecular levels. This enables
the valves to alter their shape, size and mechanical properties
during different phases of the cardiac cycle, and to respond to
the continuously changing haemodynamic conditions during
health and disease. Such changes have been shown to influence
myocardial function, coronary flow, and other organ functions.
Currently, the only valve substitute which guarantees long-
term viability of the inserted graft is the pulmonary autograft
or the Ross operation. A recent prospective randomised trial
comparing the results of the Ross operation to non-viable
aortic homograft roots showed significantly better survival
and quality of life following the Ross operation, which is
thought to be largely due to the viability of the pulmonary
autograft. Taken together, these findings support the concept
of tissue engineering viable tissue valves.
A3 5— Heart valves — concepts for tissue engineering
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Degeneration of xenografts or homografts is a major cause for
reoperation in young patients after pulmonary valve replace-
m e n t .H e r ew ep r e s e n tt h ee a r l yr e sults of fresh decellularized
pulmonary homografts (DPH) implantation compared to
glutaraldehyde-fixed bovine jugular vein (BJV) and cryopre-
served homografts (CH). Thirty-eight patients with DPH in
pulmonary position were consecutively evaluated during the
follow-up (up to 5 years), including medical examination,
echocardiography, and MRI. These patients were matched
according to age and pathology and compared to BJV (n 0
38) and CH (n 0 38) recipients. In contrast to BJV and CH
groups, echocardiography revealed no increase of transvalvular
gradient, cusp thickening, or aneurysmatic dilatation in DPH
patients. Over time, DPH valve annulus diameters converge
towards normal z-values. Five-year-freedom from explantation
was 100% for DPH; 86 ± 8 % and 88 ± 7 % for BJVand CH
conduits respectively. Additionally, MRI investigations in 17
DPH patients with follow-up time >2 years were compared to
MRI data of 20BJVrecipients.Bothpatientísgroups(DPH and
BJV) were at comparable ages (mean 12.7 ± 6.1 versus
13.0 ± 3.0 years old) and have comparable follow-up time
(3.7 ± 1.0 versus 2.7 ± 0.9 years). In DPH patients, the mean
transvalvular gradient was significantly (p 0 0.001) lower
(11 mmHg) than in the BJV group (23.2mmHg). Regurgitation
fraction was 14 ± 3 % and 4 ± 5 % in the DPH and BJV groups
respectively. In three DPH recipients, moderate regurgitation
was documented postoperatively, and remained unchanged in
follow-up. Conclusions: in contrast to conventional homografts
and xenografts, decellularized fresh allograft valves showed
improved freedom from explantation, provided low gradients
in follow-up and exhibited adaptive growth. This concept may
be transferred to myocardial tissue engineering, where most
interesting results have been obtained already.
A3 6— Relevance of understanding valve interstitial and
endothelial cell biology to tissue engineering heart valves
Adrian H. Chester
Imperial College London, National Heart & Lung Institute,
Harefield Heart Science Centre, Harefield, Middlesex UB9
6JH, UK
a.chester@imperial.ac.uk
The cellular components of heart valves play a key role in
the function and durability of these highly dynamic and
complex structures. Heart valve interstitial and endothelial
cells both possess unique phenotypic characteristics and
functional responses, which allow then to maintain the in-
tegrity of valve structure in conditions of a rapidly changing
mechanical environment. We, and others, have studied how
valve cells respond to growth factors and mechanical cues,
to promote cell proliferation and extracellular matrix secre-
tion; optimise the dispensability of valve tissue and retard
the development of calcific lesions. These properties rely on
communication between the cells and the extracellular ma-
trix, as well as paracrine signalling between endothelial and
interstitial cells. These events regulate the secretory and
contractile capacity of the interstitial cells.
Understanding the biology of valve cells and the valve
extracellular matrix isonlythefirststepinanattempttotissue
Cell Tissue Res (2012) 348:335–370 357engineering a heart valve. Comparative assessment of the
responses of candidate cells will provide a rationale for using
a particular cell type to tissue engineer a valve. Important
characteristics are the development of a valve cell phenotype,
stability of that phenotype, secretory properties, immunogenic-
ity, and an ability to respond the hemodynamic conditions
experienced by valves to promote a stable and durable structure.
In this regard, we have examined the phenotypic and functional
characteristicsofmesenchymalstemcellsisolatedfromthebone
marrowandadipose tissue.Ourdata suggestthatthesecelltypes
share some properties with valve interstitial cells, and may also
be suitable for differentiation into a valve endothelial cell phe-
notype. Understanding the properties of valve endothelial and
interstitial cells that allow them to maintain a healthy valve is
required if the function of these cells is to be recapitulated in
tissue engineered valves.
A3 7— Naturally inspired engineering of heart valves:
developmental biology meets regenerative medicine
Jonathan T. Butcher
Department for Biomedical Engineering, Cornell University,
Ithaca, NY, USA
jtb47@cornell.edu
Heart valve disease is a serious and growing clinical problem
for which the only therapy is prosthetic valve replacement.
These nonliving valves are well-suited for the elderly, but for
younger patients are poorly tolerated. Particularly in children,
there is a significant need for a living valve replacement that
can grow and remodel over time. Our lab has focused on
understanding the mechanisms by which these valves are
"naturally engineered" during embryonic development, in
order to identify paradigms that can accelerate the maturation
oftissue-engineered replacements.Twowayswedothisisby:
1) using signaling programs grounded in natural developmen-
tal valve maturation to coax stem cells naturally towards heart
valve phenotypes, and 2) identifying and replicating the
evolving developmental hemodynamic signals in tissue-
engineeredconduits.Weemploy3Dtissueprintingasameans
for creating anatomically accurate heterogeneous structures
for valve replacement. We are also using this same engineer-
ing approach to learn more about the hemodynamic causes of
congenitalheartdefects.Wehavedevelopedanewmethodfor
non-invasive microsurgery of embryonic hearts via focused
laser photoablation. We show that this technique is capa-
ble of creating models of congenital heart defects with-
out genetic mutation. Engineering approaches offer
powerful new ways of thinking about developmental
biology that can pay significant dividends towards regener-
ative medicine strategies.
A3 8— Endothelial plasticity in cardiac valves
Joyce Bischoff
Children´s Hospital Boston and Harvard Medical School,
Boston, MA, USA
joyce.bischoff@childrens.harvard.edu
The endothelium covering the aortic, pulmonary, mitral,
and tricuspid valves looks much like the endothelium
throughout the vasculature, in terms of general morphol-
ogy and expression of many endothelial markers. Closer
examination, however, reveals important differences and
hints of a unique phenotype that reflects the valvular
endothelium´s embryonic history and potentially its abil-
ity to maintain integrity and function over a lifespan of
dynamic mechanical stress. A well-studied property that
sets the cardiac valvular endothelium apart is the ability
to transition from an endothelial to a mesenchymal
phenotype — an event known as EMT. EMT is a
critical step during embryonic valvulogenesis; it can
occur in post-natal valves (Paranya et al. 2001; Paru-
churi et al. 2006), and has recently been implicated in
the adaptive response of mitral valve leaflets exposed to
a controlled in vivo setting designed to mimic the
leaflet tethering that occurs in ischemic mitral regurgi-
tation (Dal-Bianco et al. 2009). This presentation will
discuss what is known about valvular endothelial cells,
with a particular focus on EMT in post-natal, adult
valves. New data on the plasticity of valvular endothe-
lial cells will be presented (Wylie-Sears et al. 2011).
The self-renewal and multi-lineage differentiation poten-
tial of valvular ECs suggests that at subset of valvular
endothelial cells are progenitor cells, which may serve to
replenish valvular cells during normal cellular turnover and in
response to injury and disease.
Dal-Bianco JP, Aikawa E, Bischoff J, Guerrero JL, Handschumacher
MD, Sullivan S, Johnson B, Titus JS, Iwamoto Y, Wylie-
Sears J, Levine RA, Carpentier A (2009) Active adaptation
of the tethered mitral valve: Insights into a compensatory
mechanism for functional mitral regurgitation. Circulation
120:334–342
Paranya G, Vineberg S, Dvorin E, Kaushal S, Roth SJ, Rabkin E,
Schoen FJ, Bischoff J (2001) Aortic valve endothelial cells under-
go transforming growth factor-beta-mediated and non-transforming
growth factor-beta-mediated transdifferentiation in vitro. Am J
Pathol 159:1335–1343
Paruchuri S, Yang JH, Aikawa E, Melero-Martin JM, Khan ZA,
Loukogeorgakis S, Schoen FJ, Bischoff J (2006) Human
pulmonary valve progenitor cells exhibit endothelial/mesen-
chymal plasticity in response to vascular endothelial growth
factor-a and transforming growth factor-beta2. Circ Res
99:861–869
Wylie-Sears J, Aikawa E, Levine RA, Yang JH, Bischoff J (2011)
Mitral valve endothelial cells with osteogenic differentiation
potential. Arterioscler Thromb Vasc Biol 31:598–607
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A3 9— Dualism in cardiac pathogenesis: illicit use of
anabolic–androgenic steroids in a shot-put athlete homo-
zygous for a missense desmoglein-2 (Dsg2) mutation
Werner W. Franke (Presentation and Discussion Leader)
Helmholtz Group for Cell Biology, German Cancer Re-
search Center DKFZ, Im Neuenheimer Feld 280, D-69120
Heidelberg, Germany
w.franke@dkfz.de
In view of the recently increased recognition of the frequency
of ARVC/D patients carrying mutations in constitutive mo-
lecular components of the cytoskeleton and the specific junc-
tions (composite junctions, areae compositae)o ft h e
cardiomyocyte-connecting intercalated disk (see, e.g., van
Tintelen, A14, as well as Rickelt and Pieperhoff, special
article, in this issue), it is now necessary to consider the very
high ratio of young persons who take anabolic–androgenic
steroids (AAS) for the promotion of muscle growth and for
athletic performance enhancements, including athletes as well
as "bodybuilders" and persons in show business.
Although cross-striated skeletal muscle is the desired target
tissue of this drug abuse, it was not surprising to learn that
cross-striated myocardiac muscle can also increase in size and
protein mass (for early animal experiments and reviews, see
'Special Reference List'). This possible coincidence of a genetic
predisposition and widespread drug abuse is therefore a special
subject of concern, notably in connection with discussions of
cases of "sudden death" of active or former AAS abusers. As
this drug abuse usually occurs in deeply conspirative secrecy
and the persons involved, including family members, coaches,
dealers, and sports functionaries, will remain silent, it would
need a rare and special combination of circumstances to collect
and publish the information needed to present a specific case.
Therefore, we thank Mr. Gerd L. Jacobs, born April 4, 1960, in
Berlin, for permission to present his case at this meeting.
A slightly condensed summary of his life history is pre-
sented in the protocol of his interrogation by the police in
the city of Berlin for the County Court Prosecutors on
February 2 1998 (an English summary of the protocol can
be read on the author's website at http://www.dkfz.de/en/
helmholtz-zellbiologie/starting-page-Helmholtz.html).
Mr. Jacobs was an active athlete (track and field) in shot-put
and discus throw in the Berlin sports club TSC from 1972 to
1984, and finished his sports career as a sports teacher (in
the last years of his career he was among the top-ten of the
German Democratic Republic, GDR). His closest club team-
mates in shot-put included Ulf Timmermann, Olympic gold
medal winner, former world record holder and still European
record holder. Mr. Jacobs received the oral drug Oral-Turinabol
(OT), a 17-α-alkylated steroid, the most frequently used AAS
in GDR sports (Franke and Berendonk 1997). He received the
pills directly from the coach and was never informed about
possible AAS-induced damages or harmful side-effects. The
daily dose varied between two and eight pills, i.e., 10–40 mg.
In later years, the dosage was reduced to half. The drug was
given in two annual "cycles", each for 4 months.
After 1998 the cardiac health of Mr. Jacobs deteriorated
dramatically and rapidly, so that on October 1 2004 his heart
had to be replaced by a donor heart. The major statement in
the histological diagnosis was "high-grade cardiac muscle
hypertrophy with secondary myocardiac damages and myo-
cardial disarrangements".
Independently, and not aware of the AAS drug history, Posch
etal.(2008)hadfoundthattheexplantedheartaswellasother
tissues of Mr. Jacobs contained two missense mutations in the
gene encoding desmoglein-2 (V55M and V919G), i.e., one of
the two cadherin-type transmembrane glycoproteins of the
desmosomal type (Schäfer et al. 1994, 1996), the importance
of which for the development and functions in non-epithelial
tissues was first demonstrated by Eshkind et al. (2002). Mr.
JacobshasbeenreportedashomozygousforDSG-V55M,and
his father has subsequently been found to be heterozygous for
this mutation but also suffering from "dilated cardiomyopa-
thy". Ultrastructural alterations have been reported for the
intercalated disk junctions of the explanted heart, including
electron microscopy (Posch et al. 2008).
As similar heart problems, including hypertrophic and dilated
cardiomyopathies, have also been found in AAS-treated pow-
er athletes and bodybuilders (see 'Special Reference List'), the
combinations of both situations, i.e. gene mutations in one of
the constitutive molecules of the composite junctions (areae
compositae) of the myocardial intercalated disks (for Dsg2
see,for example,Borrmannetal.2006;Frankeetal. 2006; for
further recent reports on Dsg2 mutations in cardiac diseases,
see the reference thesaurus in the article by Pieperhoff and
Rickelt in this issue) and AAS-treatment (one of the most
spectacular cases in Berlin was that of the former shot-put
European vice champion Ralf Reichenbach, 48 years old),
have to be considered and discussed as a special possible
cause for the specific pathogenic developments.
Eshkind L, Tian Q, Schmidt A, Franke WW, Windoffer R, Leube RE
(2002) Loss of desmoglein 2 suggests essential functions for early
embryonic development and proliferation of embryonal stem
cells. Eur J Cell Biol 81:592–598
Franke WW, Berendonk B (1997) Hormonal doping and androgeniza-
tion of athletes: a secret program of the German Democratic
Republic government. Clin Chem 43:1262–1279
Posch MG, Posch MJ, Geier C, Erdmann B, Mueller W, Richter A,
Ruppert V, Pankuweit S, Maisch B, Perrot A, Buttgereit J, Dietz
R, Haverkamp W, Özcelik C (2008) A missense variant in
desmoglein-2 predisposes to dilated cardiomyopathy. Mol Genet
Metab 95:74–80
Cell Tissue Res (2012) 348:335–370 359Schäfer S, Koch PJ, Franke WW (1994) Identification of the ubiquitous
human desmoglein, Dsg2, and the expression catalogue of the desmo-
glein subfamily of desmosomal cadherins. Exp Cell Res 211:391–399
Schäfer S, Stumpp S, Franke WW (1996) Immunological identification
and characterization of the desmosomal cadherin Dsg2 in coupled
and uncoupled epithelial cells and in human tissues. Differentia-
tion 60:99–108
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Arrhythmogenic right ventricular cardiomyopathy (ARVC)
is a progressively degenerative cardiomyopathy, frequently
involved in juvenile sudden death. ARVC is considered a
disease of cell adhesion, because mutations in desmosomal
genes have been involved in the pathogenesis of ARVC in a
significant proportion of patients. To identify the molecular
pathogenic mechanisms involved in ARVC, we have gen-
erated cardiac-restricted desmoglein-2 (DSG2) transgenic
mice. All the transgenic lines expressing human mutated
DSG2(G100R,N266S,Q558X)resembletheclinicalfeatures
of ARVC. At the molecular level, we checked the expression
and localization of some adhesion proteins, demonstrating
changes in expression and localization of beta-catenin in
hearts of transgenic mice carrying the mutated proteins. To
establish whether the observed increase in beta-catenin
expression has a possible direct effect on Wnt signaling,
we co-injected in zebrafish embryos the WT and mutat-
ed DSG2 mRNAs with BAT-lux reporter plasmids con-
taining the luciferase enzyme cDNA under the control
of the responsive elements of Wnt/beta-catenin signal-
ing. Luciferase reporter activity occurred significantly
higher in fishes injected with mutant constructs than in
those injected with wild type.
To further examine the relationship of beta-catenin and Wnt
signaling, we co-injected dickkopf-1 (Dkk1), an inhibitor of
Wnt signalling, and we showed that Dkk1 rescued the
phenotype in embryos. In conclusion, mutations in desmo-
somal proteins can perturb the normal balance of critical
proteins in junctions and the citosol which, in turn, could
alter gene expression by circumventing normal Wnt signal-
ing pathway.
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We investigated whether intercalated disk (ID) remodel-
ling in arrhythmogenic cardiomyopathy due to desmo-
somal mutations impacts on cardiac elecrophysiological
properties before the onset of structural changes. We
studied transgenic mice with low cardiac overexpression
of N271S-dsg2 (TgNS/L, the mouse homolog of the
human mutation DSG2-N266S) at three different ages:
<2 wks, 3–4 wks and >6wks. Mice with cardiac over-
expression of wild-type dsg2 (TgWT) and wild-type
served as controls. ECG and epicardial mapping were
performed to determine ventricular conduction and ar-
rhythmia susceptibility. The structure and molecular
composition of the ID was assessed by electron micros-
copy (EM) and by immunofluorescence. Cardiomyo-
pathic changes were observed by EM in Tg-NS/L only
from >6 wks. At ECG, QRS-prolongation and sponta-
neous arrhythmias were observed in TgNS/L only from
age >6 wks. However, on epicardial mapping, ventricu-
lar activation time was prolonged in TgNS/L at 3–4w k s
( m e a n±S E M1 1 . 9±1 . 8m s ,n 0 5) compared to WT
(7.6 ± 0.6, n 0 4) and TgWT (7.4 ± 0.5, n 0 5)
(p < 0.05). In addition in this same age group, ventric-
ular arrhythmias were inducible in TgNS/L, but not in
controls. EM uncovered gap-widening at desmosomes /
adherens junctions, but not in the gap junctions, starting
at 3–4 wks exclusively in TgNS/L mice. No differences
in the level and localization of junctional proteins were
found between TgNS/L and controls. Dsg-2 mutant
mice display conduction slowing and ventricular
arrhythmias before development of cardiomyopathic
changes. This coincided with the time-point at which
junctional gap-widening was observed, suggesting that
ID integrity is required for proper electrical conduction.
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Reports about the generation of three-dimensional neo-
scaffolds for myocardial tissue engineering are limited.
The architecture provided by perfusion decellulariza-
tion of whole human-sized hearts would support the
production of three-dimensional living tissues from an
acellular matrix. The aim of this study was to evaluate
the potential of a perfusion decellularization model for
whole-heart tissue engineering.
Hearts were obtained from 12 German Landrace pigs
from a selected abattoir. After preparation, the hearts
were mounted and perfused on a modified Langendorff
decellularization model specifically constructed for this
reason. Decellularization was achieved by an ionic
detergent-based perfusion protocol. The quality of the
decellularization process was quantified by histology
and fluorescence microscopy. Data concerning the pres-
ence of residual DNA within the decellularized hearts
were measured with spectrophotometric quantification
and compared to controls. For the measurement of me-
chanical stability, a micromanometer was advanced into
the ventricle and determined LV pressure at different LV
volumes.
The here-described protocol preserved the micro- and
macroarchitecture of the hearts. After histological exam-
ination, all hearts lacked intracellular components but
retained various types of collagen, proteoglycan, and
elastin. Quantitative DNA analysis demonstrated a sig-
nificant reduction of DNA in decellularized hearts com-
pared to controls (84.32 ± 3.99ng DNA/mg tissue vs
470.13 ± 18.77ng DNA/mg tissue (p < 0.05)). Using
the decellularization protocol described in the present
study, decellularized hearts showed similar mechanical
stability as native hearts. The modified Langendorff
perfusion decellularization model described here is ap-
plicable for whole porcine hearts by removing cellular
content and DNA. The resulting three-dimensional ma-
trix provides an interesting tool for further studies in the
field of whole heart tissue engineering.
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Application of progenitor cells for differentiation in a
three-dimensional pattern is an important aspect in
tissue engineering. We report on development of a
bioreactor for three-dimensional cell culture experi-
ments using magnetically guided cell recellularization
under simulated physiologic conditions.
Stented pericardial aortic valves were constructed and
decellularized by detergents. Isolated, magnetically la-
belled human cord-blood-derived unrestricted somatic
stem cells (USSCs) were cultured in the bioreactor for
up to 130 hours (n 0 8). A magnetic field was created
around the valve within the bioreactor for specific de-
livery of circulating cells to their desired targets. In the
control group, the magnetic field was absent. The bio-
reactor enabled the retention of physiologic culture conditions
with high pulsatile flows , aerobic cell metabolism
oxygen tension (pO2 — 130 ± 20 mmHg) and physio-
logical pH values (7.4 ± 0.05) during the whole exper-
imental procedure. The histological characterization of
the matrix and cells was assessed by immunohistochem-
ical staining and electronic microscopy. Macroscopic
and histological analysis showed a homogeneous seed-
ing of the valve with USSCs in the magnet group, but
no seeding of cells could be observed in the non-
magnetic group.
Our modified multifunctional bioreactor allows for three-
dimensional culturing of human cord-blood-derived unre-
stricted somatic stem cells on pericardial stented valves with
the support of magnetic cell guidance.
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Desmoglein 2 (DSG2) mutant mice develop dilative cardiomy-
opathy characterized by cardiomyocyte necrosis, calcification,
and fibrosis (Krusche, Holthöfer et al., 2011). Since osteopontin
(OPN) is involved in calcification, inflammation, and cardiac
fibrosis (Renault et al. 2010; Matsui et al. 2004; Okamoto et al.
2011),westudiedexpressionandtissuedistributionofOPNand
its receptor, the CD44 antigen, which is involved in leukocyte
recruitment(Weberetal.1996;DeGrendeleet al.1996).mRNA
synthesis was assessed by real-time RT-PCR, and proteins were
localized by immunohistochemistry. Wild-type and homozy-
gous DSG2 mutant mice were compared. At 2 weeks, OPN
and CD44 mRNA synthesis was significantly elevated in
mutants already displaying cardiac lesions. Mutants without
pathology showed wild-type expression levels. At 8 and 12
weeks, all mutant hearts showed fibrotic alterations. The OPN
andCD44mRNAsynthesiswashigherinthemutantthaninthe
wildtype. OPN protein was localized exclusively in necrotic
cardiomyocytes.CD44+ cells wereprimarilylocalized infibrot-
ic lesions with necrotic cardiomyocytes. The highest CD44+
cell density was found in lesions of 2- and 4-week-old mutants.
Later, CD44+ cell density declined, but did not reach wild-type
levels. Staining of serial sections with the immune cell marker
CD45 implies that a high proportion of the CD44+ cells are
immune cells. In conclusion, in DSG2 mutant mice cardiac
OPN expression is associated with the onset of cardiac necrosis
and fibrosis and the perpetuation of this process. This is in
accordance with observations reported for desmin -/- mice
(Mavroidis et al., 2002). In addition, CD44+/CD45+ cells are
involved in the acute andchronicphases of thecardiomyopathy.
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Desmosomal proteins are important intercalated disc (ID)
components coupling cardiomyocytes. In humans, muta-
tions of desmosomal proteins have been implicated in
arrhythmogenic right ventricular cardiomyopathy (ARVC)
and also in dilated cardiomyopathy (DCM), which are both
characterized by fibrosis and arrhythmia (Awad et al. 2008;
Posch et al. 2008; Basso et al. 2008; Marcus et al. 2010). To
investigate the pathomechanism of desmosome-related car-
diomyopathy, we developed mice carrying a deletion in the
extracellular domains of the desmosomal cadherin desmo-
glein 2 (Dsg2). As expected, these mice develop cardiomy-
opathy with dilation, pronounced fibrosis and arrhythmia. It
has been suggested that alterations in the ID localization of
the plaque protein plakoglobin are reliable diagnostic crite-
ria for ARVC, with important implications for its pathogen-
esis occurring in concert with the related arm-repeat
proteins plakophilin 2 and β-catenin (Garcia-Gras et al.
2006; Asimaki et al. 2009; Fabritz et al. 2011). We therefore
examined the protein level and distribution of these poly-
peptides in our mouse model. For comparison, we studied
the synthesis of desmoplakin and N-cadherin. All of these
molecules are localized to the ID in the wildtype. Protein
synthesis of wild-type and mutated mouse hearts was quan-
tified by immunoblotting, revealing a reduction of the mu-
tant Dsg2 but no changes of the other polypeptides. To
examine the distribution of the respective polypeptides in
mutant heart tissue, semiquantitative immunohistology was
performed at different stages of disease development
and in different areas in relation to the fibrotic lesions.
Except for Dsg2, all proteins still localized to the ID at
the same stoichiometry as in the wildtype. We conclude
that down-regulation or mislocalization of plakoglobin
and other arm ID proteins is not obligatory for desmosome-
dependent cardiomyopathy.
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Mice carrying a deletion of the extracellular EC1/EC2-domains
of the desmosomal cadherin desmoglein 2 develop dilated
cardiomyopathy with arrhythmia and fibrosis (Krusche,
Holthöfer et al. 2011). The mutant desmoglein 2 is still targeted
to the intercalated disc region together with the other desmo-
somalproteins,albeitatreducedamounts(Krusche,Holthöferet
al.2011).Thissuggeststhatalteredadhesionmayberesponsible
for initiation of the disease process upon continued mechanical
stress. To examine this idea, cardiomyocyte ultrastructure was
examined. We find that, in contrast to the wild type, prominent
desmosomesareratherscarce.Wideningoftheintercellularcleft
occurs with complete dissociation at later time points. In addi-
tion, sarcomeric structure is disturbed, starting with altered Z-
discs. At later disease stages, mitochondria are swollen and
multiple lamellar bodies are found in the cytoplasm. Finally,
calcifying necrosis of cardiomyocytes and substitution by con-
nective tissue is observed. Taken together, the electron micro-
scopic data support the notion that the mutant desmoglein 2
leads to reduced adhesion in the intercalated disc region, which
then leads to secondary changes in sarcomeric structure and cell
viability, resulting in necrotic cell death and fibrosis.
Krusche CA, Holthöfer B, Hofe V, van de Sandt AM, Eshkind L,
Bockamp E, Merx MW, Kant S, Windoffer R, Leube RE (2011)
Desmoglein 2 mutant mice develop cardiac fibrosis and dilation.
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Tissue-engineered heart valves are in high demand in cardiovas-
cular surgery. Despite remarkable recent progress in the design
andpreparationofartificialvalvescaffoldsorofscaffoldsseeded
with certain kinds of cells in vitro, cell and molecular biological
knowledge about valvular interstitial cells (VICs), i.e., the cells
originally populating the heart valve, is astonishingly limited, in
particular with respect to their special cell–cell junctions.
Using cell biological, biochemical, and immunofluores-
cence microscopy methods as well as (immuno-)electron
microscopy, we have characterized the adhering junctions
of VICs of human, bovine, and ovine origin in situ and after
proliferation in cell culture. These junctions are of the adhe-
rens junction (AJ) type, as demonstrable by electron micros-
copy, and are similar to those found in other mesenchymal
tissues. They are composed of the transmembrane glycopro-
teins N-cadherin and cadherin-11 and the cytoplasmic
plaque proteins α-a n dβ- catenin, plakoglobin and
p120ctn. Desmosomal proteins are absent from adult VICs
in situ. Surprisingly, however, VICs in 2-D culture rather
rapidly acquire an additional plaque protein, the desmosom-
al protein plakophilin-2 (Barth et al. 2009) which, however,
recently has also been noted to occur as a novel acquisition
in the AJ plaques of diverse malignantly transformed
Cell Tissue Res (2012) 348:335–370 365mesenchymal cells or other cells with increased proliferation
rates (Rickelt et al., 2009), cardiax myxomata included (Rick-
elt et al. 2010). This quite alarming AJ alteration, however,
has been shown to be reversible in situ when these VICs are
grown in a 3D-environment composed of artificial or decellu-
larized heart valve scaffolds, mimicking the interior of native
heart valves, as well as in surgically implanted valve replace-
ment structures. In pathologically altered heart valve tissues
such as papillary fibroelastoma or myxomatous degenerated
heart valves, plakophilin-2 has generally been found to be
absent from the AJs present (Barth 2011).
Fetal heart valves of not only human, but also of porcine and
ovine origin surprisingly show — besides the ensemble of
AJ proteins known to occur in VICs of adult valves — also
the very frequent, near-regular occurrence of the additional
plaque protein plakophilin-2 in their AJs, both in situ as well
as in 2-D cultures. Remarkably, here not only VICs show
the additional plakophilin-2 but also endothelial cells of the
endocardium covering the heart valve leaflet. Therefore, a
possible role for plakophilin-2 as a marker for prolifera-
tively active mesenchymal cells present in fetal VICs as
well as in 2-D cultures of adult VICs is discussed.
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P9— The protein myozap, a major constitutive plaque
component of the composite junctions (areae compositae)
of the myocardiac intercalated disks, is also a major
and widespread protein in the cell–cell junctions of endo-
thelial cells of blood and lymph vessels
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The protein myozap, a 54-kDa polypeptide which is not a
member of any of the known junctional protein multigene
families,hasbeenidentifiedasamajorconstituentoftheplaques
of the composite junctions in the intercalated disks (IDs) con-
necting cardiomyocytes (Seeger et al. 2010). Using highly sen-
sitive and specific antibodies, we have detected myozap also in
cytoplasmic plaques of the adherens junctions (AJs) connecting
endothelial cells of the mammalian blood and lymphatic vascu-
lar system, including the desmoplakin-containing complexus
adhaerentes of the virgultar cells of lymph node sinus, and in
cultured endothelial cells. In light- and electronmicroscopic
immunolocalization experiments, we show that myozap coloc-
alizes with several proteins of desmosomal plaques as well as
with AJ-specific molecules, including VE- and N-cadherin. In
biochemical analyses of myozap, immunoprecipitation experi-
ments have revealed desmoplakin, plakophilin-2, protein ZO-1
and plectin as the most prominent complex partners. We con-
clude that myozap is a general component of cellular junctions
in the cardiovascular system, suggesting that this protein not
only serves a specific role in the heart IDs, but also functions in
the vascular system (for details see Pieperhoff et al. 2011).
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According to the prevailing textbook dogma there are two —
and only two — distinct types of cell–cell connecting, Ca
2+-
366 Cell Tissue Res (2012) 348:335–370dependent, plaque-bearing adhering junctions (AJs): the
microfilament-associated AJs, including the zonula adhaerens
and puncta adhaerentia, and the intermediate filament (IF)-
anchoring desmosomes (maculae adhaerentes), most promi-
nent for epithelial cells. The molecular composition of both
kinds of AJs has been — almost completely — elucidated,
and the specific antibodies are widely used in diagnostic
pathology and in developmental biology. Using immunocyto-
chemical, electron, and immunoelectron microscopical meth-
ods, we have revealed that in addition to these "textbook
categories" of junctions a broad range of other junctions
exists. These are the tiny puncta adhaerentia minima, the
taproot junctions (manubria adhaerentia), the plakophilin-2-
containing AJs of mesenchymal or mesenchymally derived
cell types, including malignantly transformed ones, as well
as the composite junctions (areae compositae) of the
mature mammalian myocardium, the cortex adhaerens of
the eye lens, the interdesmosomal "sandwich" or "stud"
junctions in the subapical layers of stratified epithelia (includ-
ing tumors derived therefrom), and the complexus adhaer-
entes of the endothelial and virgultar cells of the vascular
system. These junctions cannot be subsumed under one of
the major categories mentioned above but represent special
structures in their own right, appear to serve special functions,
and can may provide new markers for cell typing.
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The heart is a heterogeneous organ composed of different
types of cardiomyocytes, capillaries, nerves, and a large
variety of interstitial cells. Among interstitial cells, telocytes
(TCs), cells with telopodes (Tp), seem to be particularly
involved in intercellular communication (Popescu and
Faussone-Pellegrini 2010). Electron microscopy (EM) studies
have shown that TCs are interconnected, and have close
apposition but not conventional junctions (Franke et al.
2009) with cardiomyocytes (CM) and other interstitial cells.
In order to detail the architecture of the heterocellular and
homocellular junctions of TCs in mouse heart we performed
electron tomography (ET). EM and ET showed that Tp are
coupled each other by different types of homocellular junc-
tions: puncta adhaerentia minima, processus adhaerentes and
manubria adhaerentia. In addition, TCs establish heterocellu-
lar junctions with adult cardiomyocytes (Gherghiceanu and
Popescu 2011), cardiomyocyte progenitors or putative stem
cells (Gherghiceanu and Popescu 2010). EM study also
showed that TCs establish small atypical junctions, point con-
tacts, withmacrophages or with Schwann cells. Ultrastructural
analysis showed that TCs form an interstitial network by
homocellular junctions, and link all cardiac cells. We assume
that TCs play a significant role in cardiac physiology as
structural support for long-distance heterocellular signaling.
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P1 2— Intermediate filaments are essential for the
structure and function of the cardiac conduction system
(sinus node)
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In mammals, each heartbeat is triggered by a single electrical
impulse generated in the "pacemaker region" of the sinus node,
and then propagated to the atrial and ventricular myocytes. In the
present study, we have tried to elucidate how perturbations of the
intermediate filament (IF) cytoskeleton lead to cardiac conduc-
tion system dysfunction and arrhythmias. As is known, the
Cell Tissue Res (2012) 348:335–370 367cardiac phenotype of mutations in the muscle specific IF protein
desmin can involve — besides others — conduction defects
such as AV block and ARVD/C. In wild-type sinus nodes, we
have found that transitional cells are laterally coupled by struc-
tures wecall "lateral intercalateddiscs".By immunofluorescence
staining, these structures are positive for desmoplakin, ‚-catenin
and desmin. These structures are also evident by electron mi-
croscopy. Surprisingly, analysis of sinus node isolated from
desmin-null mice has indicated that "lateral intercalated discs"
are diminished or absent in these mice. In addition, analysis of
electrical activity (field potential recordings) of isolated sinus
nodes has revealed that there is a 50 % reduction in spike
amplitude and a 40 % increase in discharge frequency in
desmin-null mice compared to the wild-type one. These results
support the hypothesis that cells in the desmin-null sinus node
have decreased communication and coordination capacity com-
pared to wild type.
Analysis of sinus nodes from human healthy individuals who
unfortunately died young revealed that these "lateral interca-
lated disks" are also present in transitional cells, and we have
found (by immunofluorescence) that desmoplakin is a major
constituent of the subsarcolemmal cytoskeleton. Desmoplakin
forms a lattice at the subsarcolemmal level (costameres), pos-
siblyprovidingascaffoldwithveryimportantfunctionsforthe
human conduction system. Sinus nodes from young individu-
als who died from sudden cardiac death are under analysis as
candidates with plausible perturbations in these elements.
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Arrhythmogenic right ventricular cardiomyopathy (ARVC) is
characterized by loss of ventricular myocardium, which might
lead to terminal heart failure or sudden cardiac death (SCD).
ARVC is a genetically heterogeneous disorder. The purpose of
this study was to determine the prevalence of ARVC related
TMEM43 gene mutations in 22 ARVC patients.
We screened the entire TMEM43 gene of 22 ARVC index
patientspreviouslygenotypedfordesmosomal(DSG2,DSC2,
PKP2, JUP, DSP)a n dDES gene mutations (Klauke et al.
2010) by denaturing high pressure liquid chromatography
(dHPLC) and Sanger sequencing. We have identified a 70-
year-old female with borderline ARVC (Sen-Chowdhry et al.
2010) as carrier of the previously identified TMEM43 c.
1073C>T (p.S358L) mutation (Merner et al. 2008; Christen-
sen et al. 2011). Cosegregation with the ARVC phenotype
within the family has clearly been demonstrated. The fe-
male carriers of p.S358L presented a rather mild arrhyth-
mogenic phenotype, whereas three male relatives died in
the second to third decade by sudden cardiac death. In
samples of additional 37 ARVC patients, 22 DCM patients,
and 382 healthy controls, the mutation was not identified.
Although the allele frequency appears to be low in German
ARVC patients, TMEM43 should be included in molecular
genetic testing of ARVC patients.
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Arrhythmogenic right ventricular cardiomyopathy
(ARVC) is an inherited cardiomyopathy primarily of the
right ventricle (Basso et al. 1996; Marcus et al. 1982;
368 Cell Tissue Res (2012) 348:335–370Thiene et al. 1988). Five of the causal genes are coding
for desmosomal proteins (Gerull et al. 2004; McKoy et
al. 2000; Norgett et al. 2000; Sen-Chowdhry et al. 2005;
Syrris et al. 2007). Though electron microscopy of endo-
myocardial biopsies of ARVC patients revealed remodel-
ling of intercalated discs and abnormal desmosomes, the
molecular pathomechanisms are largely unknown (Basso
et al. 2006).
Paired myocardial samples from the left (LV) and right
ventricles (RV) were obtained from six non-failing (NF)
donor hearts, six ARVC patients and seven patients with
idiopathic dilated cardiomyopathy (DCM). The samples
were analyzed by Affymetrix HG-U133 Plus 2.0 arrays for
differential transcription. The analysis of our data by unsu-
pervised cluster analyses and t-tests indicated that ARVC is
a cardiomyopathy, which is not restricted to the RV. Unsu-
pervised PCA of the ARVC subgroup revealed a common
cluster for LVand RV samples of patients with desmosomal
gene mutations. Surprisingly, in the LV of ARVC patients
the gene expression of Plakophilin-2 was shown to be up-
regulated, whereas expression of Desmocollin-2 was down-
regulated. No transcriptional regulation of these genes was
observed in the RVof ARVC patients in our study. None of
the other ARVC-related desmosomal genes was regulated in
RVor LVof ARVC patients.
Our study is the first analysis of specific ARVC-related RV
and LV gene expression patterns in terminally failing human
hearts. It offers further insight into the diseasemechanismsof
ARVC and might probably reveal further candidate genes
relevant for molecular genetics of ARVC.
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P1 5— Alpha-catenin recruits vinculin to cadherin
junctions in a force-dependent manner: does it play a
role during morphogenesis of the heart?
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Several animal models have shown that proteins of the cell–
cell junctions (CCJs) such as VE-cadherin, alpha-catenin
and vinculin are important for heart development. Next to
their well-known structural role, these CCJs mediated by
cadherins are also mechanosensitive. The exact role of the
cadherin complex proteins during heart morphogenesis is
not well-understood and, in particular, the role of mechano-
transduction on this process is unknown.
Force-dependent recruitment of vinculin to CCJs is essential
for cadherin mechanosensing. To determine the role of
mechanotransduction in heart development, we aimed to
block this recruitment. As it was proposed that vinculin
recruitment depends on its binding to alpha-catenin, we
replaced the vinculin interaction domain of alpha-catenin
with the homologous domain from vinculin (its closest
homolog), obtaining an alpha-catenin/vinculin hybrid. This
construct fully restored the formation of CCJs in several
alpha-catenin negative cell lines, and actomyosin con-
traction was no longer able to induce the recruitment
of vinculin to the junctions in these cells. Our ultimate
goal is to block the alpha-catenin/vinculin interaction in
vivo during zebrafish heart development. To this end, we
started analyzing the heart phenotypes produced by injection
Cell Tissue Res (2012) 348:335–370 369of vinculin and alpha-catenin morpholinos. Both of these
showed different defects in heart development at 24 and 48
hpf. Next, we will test the defects caused by the specific loss
of junctional vinculin, by rescuing alpha-catenin depletion
with the alpha-catenin/vinculin hybrid.
In conclusion, the results in vitro suggest that force-
dependent recruitment of vinculin to CCJs can be specifi-
cally prevented by an alpha-catenin mutant that does not
perturb CCJs per se. This allows us to design in vivo experi-
ments to determine the role of cadherin mechanosensing
during heart morphogenesis.
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